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            1.0 ABSTRACT 
               The purpose of the work was to formulate and evaluate the matrix transdermal 
patches of Lamivudine for the controlled delivery of the drug in the body. The patches were 
prepared by the solvent casting method using Span-80 as a permeation enhancer. The results 
of the preliminary trials indicate the drug: polymers ratio affected the characteristics of the 
patches. This patches were prepared in different drug: polymer ( Lamivudine:HPMC and 
Lamivudine:EC ) ratios of 1:2.5, 1:5, without permeation enhancers and with permeation 
enhancers, The drug polymer interaction was investigated by FTIR and the results indicated 
no incompatibility. Lamivudine patches were evaluated for various parameters like 
thickness, folding endurance, percentage moisture loss, percentage moisture absorption, 
drug content uniformity, stability studies, in vitro skin permeation, skin irritation test, 
statistical analysis by ANOVA, in vivo studies and invitro/invivo . The prepared transdermal 
patches were subjected to in vitro drug permeation study by using rat skin in Phosphate 
Buffer pH 7.4 for 24 hrs. The comparative statistical analytical data (ANOVA) showed ‘p’ 
value < 0.0001which suggest that the prepared formulations are extremely significant for 
transdermal delivery. The formulation (FPE2) ratio 1:5 of (Lamivudine:HPMC) patch with 
permeation enhancer showed best result among all formulation. This formulation (FPE2) 
was subjected to in-vivo studies by using rat. For in vivo studies patches were administered 
transdermally to rats, while a standard solution of 10µg/ml was used as a control, and 
collected the plasma at different time interval and analyzed by HPLC technique, and carried 
out the in-vitro in-vivo correlation. Thus showed a near correlation for in-vitro and in-vivo 
studies. 
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2.0 INTRODUCTION 
Transdermal drug delivery is the non-invasive delivery of medications from the 
surface of skin-the largest and most accessible organ of human body- through its layers, to 
the circulatory system. TDDS offers many advantages over conventional injection and oral 
methods. It reduces the load that the oral route commonly places on the digestive tract and 
liver. It enhances patient compliance and minimizes harmful side effects of a drug caused 
from temporary overdose. Another advantage is convenience, especially notable in patches 
that require only once weekly application. Such a simple dosing regimen can aid in patient 
adherence to drug therapy. Designing and development of transdermal patches can be 
described as state of the art. The development of TDDS is multidisciplinary activity that 
encompasses fundamental feasibility studies starting from the selection of drug molecule to 
the demonstration of sufficient drug flux in an ex vivo and in vivo model followed by 
fabrication of a drug delivery system that meets all the stringent needs that are specific to the 
drug molecule (physicochemical and stability factors), the patient (comfort and cosmetic 
appeal), the manufacturer (scale up and manufacturability) and most important the 
economy1.  
The current transdermal delivery systems have evolved as a successful alternative to 
systemic drug delivery. Despite their relatively higher costs, transdermal delivery systems 
have proved advantageous for delivery of selected drugs, such as estrogens, testosterone, 
clonidine, nitroglycerin, scopolamine, fentanyl, and nicotine. Compared to oral dosage 
forms, these systems offer not only improved patient compliance, but also superior 
uniformity of drug concentrations in plasma throughout their duration of use. Most 
transdermal patches are designed to release the active ingredient at a zero-order rate for a 
period of several hours to days following application to the skin.2  
             Recently there has been an increasing awareness that the benefits of intravenous 
drug infusion can be closely duplicated, without its potential hazards, by continuous 
transdermal drug administration through skin3.     
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Acquired immune deficiency syndrome (AIDS), which threatens to cause a great 
plague in the present generation, was first identified in California in 1981.  AIDS is 
considered to be an epidemic and according to estimates from the UN AIDS/WHO 2007 
report on the global AIDS epidemic showed 33.2 million people lived with HIV, including 
2.5 million children. An estimated 2.5 million (range 1.8-4.1 million) people were newly 
infected in 2007, including 420,000 children and it killed an estimated 2.1 million people, 
including 330,000 children. India has an estimated 2.5 million infections and an estimated 
adult prevalence of 0.36%. Life expectancy has fallen dramatically in the worst-affected 
countries; for example, in 2006 it was estimated that it had dropped from 65 to 35 years in 
Botswana. The annual number of AIDS deaths can be expected to increase for many years to 
come, unless more effective and patient compliant anti-retroviral medications are available 
at affordable prices.   The major drawbacks of anti retroviral drugs for the treatment of 
AIDS are their adverse side effects during long-term therapy, poor patient compliance and 
huge cost of the therapy4. 
 
Lamivudine (3TC), an antiretroviral is commonly used in the treatment of HIV 
infected patients. Most of the antiretroviral including lamivudine are virustatic in nature and 
they must be administered for the life span of the patient (Bettyet al., 2000). Despite being 
quite effective on oral administration, 3TC exhibits dose dependent toxic side effects such as 
hepatotoxicity, hyperglycemia, hyperlipidemia, lactic acidosis, lipodystropy, osteonecrosis, 
osteoporosis, osteopenia, skin rashes, resulting from excessive systemic concentration. 
These side effects often require dosage reduction or even cessation of treatment, since 
conditions like lactic acidosis may even be fatal (Stephen et al., 1991 & Greenberg et al., 
2004). Thus, despite their undisputed effectiveness several complicated clinical issues are 
associated with the use of these agents. Thus, the problems associated with oral 
administration of 3TC led us to explore the possibilities of designing novel drug delivery 
system for lamivudine with an alternative route of administration. Novel drug delivery 
carriers such as transdermal patches are very versatile to suit the delivery of various drug 
molecules (Joshi, 2000 & Mirachandani et al., 1993). To fulfill the need of long-term 
treatment with anti-HIV agents controlled drug delivery systems are preferred. Thus it was 
proposed that a noninvasive zero – order delivery such as the transdermal route is desirable, 
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as controlled delivery via oral route retains most of the drawbacks of conventional oral 
delivery. Percutaneous absorption of a number of antiretroviral has been studied indicating a 
promising future for this route for the delivery of  antiretroviral (Bouwstra et al., 2002, 
Karali et al., 1995, Thomas et al., 2003)5. 
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3.0 REVIEW OF LITERATURE 
 
STRUCTURE OF SKIN 
 
      
 
Fig.1 Structure of skin 
 The skin of an average adult body covers around 2m2 of the surface area and receives 
1/3rd of all blood circulating through the body. It has a thickness of only a fraction of mm, the 
skin separates underlying blood circulation network from the outside environment.  
• An average human skin surface is known to contain, on the average, 40 to 70 hair follicles 
and 200 to 250 sweat ducts on each square cm of skin area.  
• Presently there is an increasing recognition that skin can also serve as the part of 
administration for systemically active drugs.  
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• In this case, the drug applied topically will be absorbed first into blood circulation and then 
be transported to target tissues, which would be rather remote from the site of drug 
application to achieve its therapeutic doses.  
              The skin is a multi layer organ composed of many histological layers. It is generally 
described in terms of three major tissue organs. 
       1. The Epidermis  
       2. The Dermis  
       3. The hypodermis  
The Epidermis 
Epidermis is the most superficial layer and is composed of stratified squamous type of 
epithelium. From outside inward stratified epithelium may be divided in to 5 layers, they are, 
      a. Stratum Corneum  
      b. Stratum Lucidum  
      c. Stratum Granulosum  
      d. Stratum Spinosum  
      e. Stratum Germinatum  
a. Stratum Corneum 
The Stratum Corneum is most superficially placed and consists of many layers of 
compacted, flattened, dehydrated, and keratinized cells. They are dead cells converted into 
proteins and are continuously shed. The cell outlines are indistinct and the nuclei are absent. The 
stratum Corneum has a water content of only ~20% as compared to normal 70% in 
physiologically active Stratum Germinatum. This layer is thickest at the sole and the palm and 
thinnest at the lip. Hairs, loops, nails, feathers, scales, etc., are special outgrowth of this layer. 
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b. Stratum Lucidum 
This is a thin more or less transparent layer 3 to 5 cells deep placed below the stratum 
corneum. The cell outlines are indistinct and the nuclei are absent. The cells contain droplets of 
“eleidin” which is precursor of keratin. 
 
c. Stratum Granulosum 
Stratum Granulosum is situated below the stratum Lucidum and consists of 3 to 5 layers 
of flattened polyhydral cells filled with keratohyalin granules which takes a deep stain with 
haematoxylin. 
 
d. Stratum Spinosum 
This is a broad layer of variable thickness and is made up of polyhedral cells is 
apparently covered with minute spines, which interdigitate with similar spines of adjacent cells. 
There are consequently known as “prickle cells”. As the microscopic studies indicate that the 
prickle cells are in fact cytoplasmic protrusions and the branches from two cells actually do not 
have cytoplasmic continuity, but attached by well developed cytoplasmic nodes called as 
desmosomes. 
 
e. Stratum Germinatum 
This is growing layer is composed of a single layer of columnar epithelium which has 
got transverse, thin, short cytoplasmic processes on its basal lamina by means of which they 
anchor the epithelium to the underlying dermis. These cuboidal to columnar cells with oblong 
nuclei, placed perpendicularly on the basement membrane, produce new cells to replace those of 
the above layers by the process of mitosis.  
 
The Dermis 
The true skin is made up of connective tissue and lies below the epidermal layer which it 
supports and binds to the underlying tissues. It is made up chiefly of collagenous and elastic 
fibres which provide it with a tensile strength equal to that of a thin steel wire. This layer is 
utilized for the production of leather after chemical processing. From the structural point of 
view the superficial part of the dermis is compact and forms the papillary layer because it sends 
innumerable finger like projections into the prickle cell layer of epidermis. The deeper part of 
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the dermis is composed of rather loose connective tissue and is infiltrated with fat. The reticular 
layer of he dermis merges imperceptibly in to subcutaneous layer of fat. 
 
Functions of skin 
   Protection 
Stratum Corneum which is the outer most layer is horny and formed by the keratinized 
stratified epithelial cells resist the action of external agencies. It protects the internal individual 
injury and bacterial invasion. The nails are also defensive appendages of the skin. 
 
Regulation of body temperature 
Cutaneous vasoconstriction diverts the blood to the interior of the body and so 
diminishes heat loss. This is an important mechanism of protection against cold environment. 
Vasodilatation of the skin helps in elimination of heat from the body. 
 
General sensation 
The skin serves as the medium for receiving the general sensation. Tough, pain, 
temperature, etc., are subserved by the respective nerve endings present in the skin. The hair roots 
are richly supplied with nerves. Consequently, slight movement of the hair, such as by a blast of 
wind arouses. In this way hairs help the sensory functions of the skin. 
 
Gaseous exchange 
Absorption of oxygen and excretion of CO2 may go on to a considerable extent through 
the skin in those animals whose skin is thin and moist, e.g. frogs. It is said that it can be carried 
to such an extent that these animals may live even after the extirpation of the lungs or in the 
hibernating period when the lungs do not function. 
 
Absorption 
Waxy layer hinders water absorption though the skin. But the skin is not completely 
waterproof and on prolonged exposure to water, there is water absorption causing swelling of 
the Stratum corneum. Lipids are easily permeable through the skin. Lipid-soluble substances 
like vitamins are easily absorbed through the skin.6  
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DRUG DELIVERY ROUTES ACROSS HUMAN SKIN  
Drug molecules in contact with the skin surface can penetrate by three potential 
pathways: through the sweat ducts, via the hair follicles and sebaceous glands(collectively 
called the shunt or appendageal route), or directly across the stratum corneum (Fig. 1). The 
relative importance of the shunt or appendageal route versus transport across the stratum 
corneum has been debated by scientists over the years (eg. [5-7]) and is further complicated 
by the lack of a suitable experimental model to permit separation of the three pathways. In 
vitro experiments tend to involve the use of hydrated skin or epidermal membranes so that 
appendages are closed by the swelling associated with hydration. Scheuplein and 
colleagues7,8 proposed that a follicular shunt route was responsible for the presteady-state 
permeation of polar molecules and flux of large polar molecules or ions that have difficulty 
diffusing across the intact stratum corneum. However it is generally accepted that as the 
appendages comprise a fractional area for permeation of approximately 0.1% 9, their 
contribution to steady state flux of most drugs is minimal. This assumption has resulted in 
the majority of skin penetration enhancement techniques being focused on increasing 
transport across the stratum corneum rather than via the appendages. Exceptions are 
iontophoretic drug delivery which uses an electrical charge to drive molecules into the skin 
primarily via the shunt routes as they provide less electrical resistance, and vesicular 
delivery. 
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Fig: 2 Simplified representation of skin showing routes of penetration: 1. through the 
sweat ducts; 2. directly across the stratum corneum;3. via the hair follicles 
 
 Considerable research effort has been directed towards gaining a better 
understanding of the structure and barrier properties of the stratum corneum. A recent 
review by Menon provides a valuable resource10. The stratum corneum consists of 10-15 
layers of corneocytes and varies in thickness from approximately 10-15 µm in the dry state 
to 40 µm when hydrated11,12,13. It comprises a multi-layered “brick and mortar” like structure 
of keratin-rich corneocytes(bricks) in an intercellular matrix (mortar) composed primarily of 
long chain ceramides, free fatty acids, triglycerides, cholesterol, cholesterol sulfate and 
sterol/waxesters14. However it is important to view this model in the context that the 
corneocytes are not brick shaped but are polygonal, elongated and flat (0.2-1.5 µm thick, 34-
46 µm in diameter). The intercellular lipid matrix is generated by keratinocytes in the mid to 
upper part of the stratum granulosum discharging their lamellar contents into the 
intercellular space. In the initial layers of the stratum corneum this extruded material 
rearranges to form broad intercellular lipid lamellae15, which then associate into lipid 
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bilayers16,17, with the hydrocarbon chains aligned and polar head groups dissolved in an 
aqueous layer (Fig. 2). As a result of the stratum corneum lipid composition, the lipid phase 
behavior is different from that of other biological membranes. The hydrocarbon chains are 
arranged into regions of crystalline, lamellar gel and lamellar liquid crystal phases thereby 
creating various domains within the lipid bilayers18. The presence of intrinsic and extrinsic 
proteins, such as enzymes, may also affect the lamellar structure of the stratum corneum. 
Water is an essential component of the stratum corneum, which acts as a plasticizer to 
prevent cracking of the stratum corneum and is also involved in the generation of natural 
moisturizing factor (NMF), which helps to maintain suppleness.  
 
In order to understand how the physicochemical properties of the diffusing drug and 
vehicle influence permeation across the stratum corneum and there by optimize delivery, it 
is essential to determine the predominant route of drug permeation within the stratum 
corneum. Traditionally it was thought that hydrophilic chemicals diffuse within the aqueous 
regions near the outer surface of intracellular keratin filaments (intracellular or transcellular 
route) whilst lipophilic chemicals diffuse through the lipid matrix between the filaments 
(intercellular route)19 ( Fig. 3). 
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Fig: 3 Diagrammatic representation of the stratum corneum and the intercellular and 
transcellular routes of penetration20 
 
However, this is an oversimplification of the situation as each route cannot be viewed in 
isolation. A molecule traversing via the transcellular route must partition into and diffuse 
through the keratinocyte, but in order to move to the next keratinocyte, the molecule must 
partition into and diffuse through the estimated 4-20 lipid lamellae between each keratinocyte. 
This series of partitioning into and diffusing across multiple hydrophilic and hydrophobic 
domains is unfavorable for most drugs. Consequently, based on more recent data (for 
example15,21,22,23,24 ) the intercellular route is now considered to be the major pathway for 
permeation of most drugs across the stratum corneum. 
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Percutaneous absorption 
         The drug molecules is of particular importance in the case of transdermal drug delivery 
systems because the drug has to be absorbed to an adequate extent and rate to achieve and 
maintain uniform, systemic, therapeutic levels throughout the duration of use. In general, 
once drug molecules cross the stratum corneal barrier, passage into deeper dermal layers and 
systemic uptake occurs relatively quickly and easily. Generally, drug absorption into the 
skin occurs by passive diffusion. The rate of drug transport across the stratum corneum 
follows Fick’s Law of Diffusion25. 
 
Fick’s Law of Diffusion as applied to drug transport across stratum   
corneum4  
 
dM = D.∆C.K  
               dt         h  
  where: 
 dM/dt   is the steady-state flux across stratum corneum 
 
 D  =  is the diffusion coefficient or diffusivity of drug 
molecules 
 
 ∆C =  is the drug concentration gradient across the 
stratum    corneum  
 
 K = is the partition coefficient of the drug between skin 
and formulation medium, and  
 
 h   =  is the thickness of the stratum corneum  
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KINETICS OF TRANSDERMAL PERMEATION 
 
      Fig: 4 
Knowledge of skin permeation kinetics is vital to the successful development of 
transdermal therapeutic systems. Transdermal permeation of a drug involves the following 
steps: 
      1. Sorption by stratum corneum. 
      2. Penetration of drug through viable epidermis. 
      3. Uptake of the drug by the capillary network in the dermal papillary layer. 
Thus permeation can be possible only if the drug possesses certain physiochemical 
properties. 
The rate of permeation across the skin is given by: 
                                              dQ /dt      = Ps ( Cd – Cr )              .   
Where Cd and Cr are the concentration of the skin penetrant in the donor 
compartment i.e. on the surface of stratum corneum and in the receptor compartment i.e. 
body respectively. Ps is the overall permeability coefficient of the skin tissue to the 
penetrant. This permeability coefficient is given by the relationship:  
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                                           Ks D ss 
                   Ps     =       ------------------ 
                                                   hs       
where Ks is the partition coefficient for the interfacial partitioning of the penetrant 
molecule from a solution medium or a transdermal therapeutic system on to the stratum 
corneum, Dss is the apparent diffusivity for the steady state diffusion of the penetrant 
molecule through a thickness of skin tissues and hs is the overall thickness of skin tissues. 
As Ks, Dss and hs are constant under given conditions the permeability coefficient Ps for a 
skin penetrant can be considered to be constant. From equation (1) it is clear that a constant 
rate of drug permeation can be obtained only when Cd >> Cr i.e. the drug concentration at 
the surface of the stratum corneum Cd is consistently and substantially greater than the drug 
concentration in the body Cr.  
The equation becomes: 
                                                 dQ /dt        =      Ps Cd  
And the rate of skin permeation is constant provided the magnitude of Cd remains 
fairly constant throughout the course of skin permeation. For keeping Cd constant the drug 
should be released from the device at a rate Rr i.e. either constant or greater than the rate of 
skin uptake Ra, i.e Rr >> Ra . 
Since Rr >> Ra, the drug concentration on the skin surface Cd is maintained at a level 
equal to or greater than the equilibrium solubility of the drug in the stratum corneum Cs. i.e. 
Cd>>Cs. Therefore a maximum rate of skin permeation is obtained and is given by the 
equation:  
                                                  (dQ/dt)
 m    =    PsCs 
  From the above equation it can be seen that the maximum rate of skin permeation depends 
upon the skin permeability coefficient Ps and is equilibrium solubility in the stratum 
corneum Cs. Thus skin permeation appears to be stratum corneum limited. 
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Kinetics of Drug Release From TDDS 26.   
Kinetics of release from monolithic systems26 
In monolithic system the drug diffuses through the polymer and then partition into 
the skin from the system. Matrix diffusion occurs down the concentration gradient at a rate 
that is controlled by diffusion coefficient of drug molecular size of the drug. For the system, 
which release the drug by diffusion, were proposed by Higuchi. The steady state drug 
release from the matrix according to Higuchi eqution. 
                 
 
Where, 
Q - Amount of drug release per unit area of the matrix exposed to the solvent. 
A - Total concentration of drug in matrix. 
D - Diffusion coefficient of drug in the permeation fluid. 
  ε - Porosity of the matrix. 
τ -Tortousity of the matrix. 
  Cs - Solubility of drug in dissolution medium. 
  t - Time. 
 It was assumed that A was greater that Cs by factor of at least 3 or 4 justifying   the 
use of this particular equation. Assuming that the diffusion coefficient remain constant 
during release, then equation (1) may be reduced to 
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Thus for diffusion controlled mechanism, a plot of percentage of drug release per 
unit area of the matrix against square root of time should be linear.The most important 
assumption in the theory of Higuchi is that the total surface areas of the matrix dose not 
change significantly during diffusion run. Two modes of behavior in such systems can be 
expected during diffusion studies, 
           i. The drug will be released in first mode after an initial swelling of matrix. 
           ii In another mode, the drug may be diffused out without any swelling or change of 
geometry of the matrix.  
 Kinetic Release from membrane controlled systems26 
 In membrane controlled system, first the drug will partition from reservoir into 
polymer matrix that comprises the rate controlling membrane. In the membrane, diffusion 
will occur down a concentration gradient at a rate which will be controlled by the diffusion 
coefficient of the drug in the polymer. Once the drug has diffused through the rate 
controlling membrane it will partition into skin,                         
diffusion occurs down the concentration gradient at a rate that is controlled by diffusion 
coefficient of drug in the polymer. 
   The rate of permeation dq/dt across various layer of skin tissue can be expressed as. 
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Where, 
Cd - Concentration of drug in donor compartment. 
Cr - Concentration of drug in receptor compartment. 
Ps - Overall permeability coefficient. 
Where as Ps can be defined as  
                        
   
 
Where, 
Ks/d- Partition coefficient. 
 
Dss - Apparent diffusivity. 
 
hs - Thickness of the skin tissues.                
 
Ps can be considered as constant, if Ks/d, Dss and hs terms in above equation are 
constant under a given set of conditions. Equation 1 suggest that to achieve a constant rate of 
drug permeation, one needs to maintain a condition in which the drug concentration of the 
surface of stratum corneum (Cd) is consistently and substantially greater than the drug 
concentration in the consistently and substantially greater than the drug concentration in the 
receptor side (Cr) i.e., Cd>>Cr under such condition equation1 can be reduced to,                       
 
By making Cd greater than Cr, the drug concentration on the skin surface is maintained at 
level equal to or greater than equilibrium (or saturation) solubility of drug in stratum 
corneum Cse i.e., Cd ≥Cse then equation 3 can be written as, 
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Penetration enhancers 27              
         The perfect barrier properties of the epidermis restricts the transport through the skin 
to molecules with certain properties such as low molecular weight (< 500 Dalton), moderate 
lipophilicity (octanol–water partition coefficient between 10 and 1000), and modest melting 
point (< 200 °C) correlating with good solubility. 
 Dermatological and cosmetic preparations frequently contain active principles which 
can only act when they penetrate at least the outermost layer of the skin. However, the 
efficacy of topically applied actives is often suboptimal because the transport into the skin is 
slow due to the resistance of the outermost layer of the skin, the stratum corneum. Most 
small water-soluble non-electrolytes therefore diffuse into the systemic circulation a 
thousand times more rapidly when the horny layer is absent. Thus, a variety of means have 
been studied in attempts to overcome this barrier. Such strategies include physical, 
biochemical, and chemical methods. 
 
Supersaturation 
 Supersaturation is a means to increase skin penetration without alteration of stratum 
corneum structure. The mechanism of enhancement is based simply on the increased 
Thermodynamic activity of the drug. This increases the concentration gradient (c0 – ci) in 
the Fick’s law and thus forces the active principle out of the formulation and into and across 
the stratum corneum. Several methods can be used to produce supersaturated systems: 
 Heating and subsequent cooling 
 Removal of a solvent 
 Reaction of two or more solutes to produce a compound which is less soluble 
 Addition of a substance to a solution that reduces the solubility of the solute. 
 
Water as penetration enhancer 
     Hydration of the stratum corneum is one of the primary measures to increase the 
penetration of most active compounds. Water opens up the compact structure of the horny 
layer. The water content of the horny layer can be increased either by delivering water from 
the vehicle to the skin or by preventing water loss from the skin when partially occlusive 
formulations are applied to the skin. 
 
 20
Chemical Enhancers 
Several excipients are able to promote the transport of an active substance across the 
skin barrier by a variety of mechanisms. The most important are: 
            • Extraction of lipids from the stratum corneum 
            • Alteration of the vehicle/skin partitioning coefficient 
            • Disruption of the lipid bilayer structure 
            • Displacement of bound water 
            • Loosening of horny cells 
            • Delamination of stratum corneum 
  Chemical enhancers can be categorized into different groups. Solvents like alcohols, 
alkylmethyl sulfoxides, and polyols mainly increase solubility and improve partitioning 
coefficient. Moreover, some solvents, e.g. Dimethlysulphoxide (DMSO), ethanol, may 
extract lipids, making the stratum corneum more permeable. Oleic acid, Azone (epsilon-
Laurocapram), and isopropyl myristate are typical examples of chemical enhancers which 
intercalate into the structured lipids of the horny layer where they disrupt the packing. This 
effect makes the regular structure more fluid and thus increases the diffusion coefficient of 
the permeant. Ionic surfactants, decylmethyl sulfoxide, DMSO, urea interact with the keratin 
structure in the corneocytes. This opens up the tight protein structure and leads to an 
increased diffusion coefficient D mainly for those substances which use the transcellular 
route. 
 
 
 
 
 
  
 
 
 
Fig: 5 Different Examples of Chemical Enhancers 
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 An unfortunate feature of many potent chemical enhancers is that they irritate due to 
their ability to interact effectively with the corneocytes and the intercellular lipid structure.  
 
Advantages of Transdermal patches  
 Provide relatively steady and sustained drug concentration in plasma in contrast to 
conventional systems where peaks and troughs are a common feature.  
 Variability due to factors such as pH intestinal motility, food intake, etc, which make 
vast difference in the bioavailability of the drugs given through oral route, are not 
existent.  
 The hepatic first pass metabolism is avoided.  
 A constant rate of absorption is possible in a vast variety of adverse patient population.  
 Ease of administration and patient convenience.  
 Drug input terminable by mere removal of the Transdermal patches.  
 Drugs that cause gastro intestinal upset can be good candidates for Transdermal delivery 
because this method avoids direct effects on stomach and intestine.  
 Increased therapeutic value due to avoidance of hepatic first pass effect, gastro intestinal 
irritation and low absorption problem.  
 Drugs that are having short biological half-life can be given by this therapeutic systems 
and it also reduces dosing frequency.  
 Transdermal patches are used for cessation of tobacco smoking.  
Disadvantages of Transdermal patches 
 Can be used only for drugs, which require very small plasma concentrations for action.  
 Local irritation and arythmea are possible. Enzymes in epidermis or derived from micro 
organisms present on the skin may denature the drugs.  
 Another significant disadvantage of Transdermal drug delivery is that skin is less 
permeable because it serves as protective barrier for the entry of foreign particles.  
 In order to maintain constant release states, transdermal patches must contain surplus of 
active drug.  
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Preparation Of Different Types Of Transdermal Patches:  
 Several system designs have been used in development and fabrication of TDDSs. 
The systems that have been introduced in market can be classified into following types28,29:  
Current controlled transdermal – release systems can be classified in to four categories: 
1. Membrane permeation – controlled system in which the drug permeation is 
controlled by polymeric membranes. 
2. Adhesive dispersion – type system in which drug is dispersed in to an adhesive 
polymer. 
3. Matrix diffusion- controlled system in which the drug is homogeneously dispersed in 
a hydrophilic polymer. 
4.
 Micro reservoir – controlled system in which microscopic spheres of drug reservoir 
are dispersed in a polymeric matrix.3  
5.
 Drug in adhesive type- are directly in corporated into the organic solvent based 
pressure sensitive adhesive solution, mixed, cast as a thin film. 
 
Matrix Type Transdermal Patch 
Drug reservoir is prepared by dissolving the drug and polymer in a common solvent. 
The insoluble drug should be homogenously dispersed in hydrophilic or lipophillic polymer. 
The required quantity of plasticizer like dibutylpthalate, triethylcitrate, polyethylene glycol 
or propylene glycol and permeation enhancer is then added and mixed properly. The 
medicated polymer formed is then molded into rings with defined surface area and 
controlled thickness over the mercury on horizontal surface followed by solvent evaporation 
at an elevated temperature. The film formed is then separated from the rings, which is then 
mounted onto an occlusive base plate in a compartment fabricated from a drug impermeable 
backing. Adhesive polymer is then spread along the circumference of the film30,31. 
Commonly used polymers for matrix are cross linked polyethylene glycol, eudragits, ethyl 
cellulose, polyvinylpyrrolidone and hydroxypropylmethylcellulose.  
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 The dispersion of drug particles in the polymer matrix can be accomplished by either 
homogenously mixing the finely ground drug particles with a liquid polymer or a highly 
viscous base polymer followed by cross linking of polymer chains or homogenously 
blending drug solids with a rubbery polymer at an elevated temperature32. The matrix 
system is exemplified by the development of Nitro-Dur®. Advantages of matrix patches 
include absence of dose dumping, direct exposure of polymeric matrix to the skin and no 
interference of adhesive. Design of matrix type patch is shown in Figure 6.  
 
 
Fig: 6  Matrix Type Transdermal Patch 
The rate of drug release from this type of system is defined as : 
                             ACp Dp    ½ 
 dQ/dt  = ------------------------------ 
                                                                                   2t   
 Where A is the initial drug loading dose dispersed in the polymer matrix and Cp and 
Dp are the solubility and diffusivity of the drug in the polymer respectively. Since, only the 
drug species dissolved in the polymer can release, Cp is essentially equal to CR , where CR is 
the drug concentration in the reservoir compartment. 
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Reservoir Type Transdermal Patch 
The drug reservoir is made of a homogenous dispersion of drug  particles suspended 
in an unleachable viscous liquid medium (e.g. silicon fluids) to form a paste like suspension 
or gel or a clear solution of drug in a releasable solvent (e. g. ethanol). The drug reservoir 
formed is sandwiched between a rate controlling membrane and backing laminate33.  
 The rate controlling membrane can be nonporous so that the drug is released by 
diffusing directly through the material, or the material may contain fluid filled micropores in 
which case the drug may additionally diffuse through the fluid, thus filling the pores. In the 
case of nonporous membrane, the rate of passage of drug molecules depends on the 
solubility of the drug in the membrane and the thickness of membrane. Hence, the choice of 
membrane material is dependent on the type of drug being used. By varying the composition 
and thickness of the membrane, the dosage rate per unit area of the device can be controlled. 
Mostly EVA, ethyl cellulose, silicon rubber and polyurethanes are used to prepare rate 
controlling membranes1,34,35,36. EVA is used most frequently to prepare rate controlling 
membrane in transdermal delivery systems because it allows the membrane permeability to 
be altered by adjusting vinyl acetate content of polymer. Polyurethane membranes are 
suitable especially for hydrophobic polar compounds having low permeability through 
hydrophobic polymers such as silicon rubber or EVA membrane37.  
 Liang et al., (1990) studied controlled release of scopolamine through EVA 
membrane in transdermal patch formulations and release rates were compared with 
uncontrolled reservoirs. It was found that an EVA membrane patch released scopolamine at 
a constant rate for more than 72 hours35.  
 Krishna and Pandit (1994) prepared three transdermal formulations containing 
propranolol hydrochloride in a hydrophilic polymer matrix, one without rate controlling 
membrane and other two with EVA rate controlling membranes of different thickness. It 
was found that increased thickness of EVA led to greater retention of the drug in device and 
zero order profile was observed with EVA36.  
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 Rate controlling membrane may be prepared by solvent evaporation method or 
compression method. In case of solvent evaporation method, polymer is dissolved in solvent 
with or without plasticizer. Then the solution is poured on the horizontal surface and left for 
evaporation of solvent in order to obtain a thin film.  In case of compression method, 
polymer is compressed with required force at high temperature for specific period of time38. 
Drugs that require relatively high doses or greater permeation enhancement, such as 
testosterone, use liquid reservoir systems. But the application of enhancers and adhesive 
technologies has allowed many drugs that were initially administered in liquid reservoirs to 
be used as matrix type systems e.g. estradiol, nicotine, nitroglycerine39. The main advantage 
of reservoir type patches is that this patch design can provide a true zero order release 
pattern to achieve a constant serum drug level. Examples of marketed preparations are 
Duragesic®, Estradem® and Androderm®. Figure 7 illustrates the design of reservoir type 
of patch.  
 
Fig: 7 Reservoir Type Transdermal Patch 
The rate of drug release from this drug reservoir gradient controlled system is given by: 
                  Ka/r . Da  x  A ( ha ) 
dQ/dt =  ------------------------------ 
                            ha ( t ) 
In the above equation, the thickness of the adhesive layer for drug molecules to 
diffuse through increases with time ha (t). To compensate for this time dependent increase in 
the diffusional path due to the depletion of drug dose by release, the drug loading level is 
also  increased with the thickness of diffusional path A (ha). 
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Membrane matrix hybrid type patch 
This is the modification of reservoir type transdermal patch. The liquid formulation 
of the drug reservoir is replaced with a solid polymer matrix (e.g. polyisobutylene) which is 
sandwiched between rate controlling membrane and backing laminate40. Examples of 
marketed preparations are Catapress® and TransdermScop®.  
 
 
 
Fig: 8 Membrane matrix hybrid type patch 
The intrinsic rate of drug release from this type of drug delivery system is defined 
by:              
                                     
                                                    Cr 
dQ/dT  =  ------------------- 
                                                         1/Pm + 1/Pa 
 
Where Cr is the drug concentration in the reservoir compartment and Pa and P m are 
the permeability coefficients of the adhesive layer and the rate controlling membrane , Pm is 
the sum of permeability coefficients simultaneous penetrations across the pores and the 
polymeric material. Pm and Pa, respectively, are defined as follows.             
                                                Km/r .Dm 
Pm =  ------------- 
                                                        hm        
 
                                                 Ka/m .Dm 
 Pa =  ------------- 
                                                          ha        
 where Km/r and Ka/m are the partition coefficients for the interfacial partitioning of 
drug from the reservoir to the membrane and from the membrane to adhesive respectively; 
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Dm and Da are the diffusion coefficients in the rate controlling membrane and adhesive 
layer, respectively; and hm and ha are the thickness of the rate controlling membrane and 
adhesive layer, respectively. 
Micro reservoir type transdermal patch 
The drug reservoir is formed by suspending the drug solids in an aqueous solution of 
water miscible drug solubilizer e.g. polyethylene glycol. The drug suspension is 
homogenously dispersed by a high shear mechanical force in lipophillic polymer, forming 
thousands of unleachable microscopic drug reservoirs (micro reservoirs). The dispersion is 
quickly stabilized by immediately cross linking the polymer chains in-situ which produces a 
medicated polymer disc of a specific area and fixed thickness. Occlusive base plate mounted 
between the medicated disc and adhesive form backing prevents the loss of drug through the 
backing membrane41,42. This system is exemplified by development of Nitrodisc®. Micro 
reservoir type transdermal system is shown in Figure 9.  
 
 
 
Fig: 9 Micro reservoir type transdermal patch 
The rate of drug release in this system is defined by:           
                   Ka/r . Da 
 dQ/dt =   --------------  x    Cr 
           ha 
 Where Ka/r is the partition coefficient for the interfacial partitioning of the drug from 
the reservoir layer to adhesive layer. 
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Drug in adhesive type transdermal patch  
The drug and other selected excipients, if any, are directly incorporated into the 
organic solvent based pressure sensitive adhesive solution, mixed, cast as a thin film and 
dried to evaporate the solvents, leaving a dried adhesive matrix film containing the drug and 
excipients. This drug in adhesive matrix is sandwiched between release liner and backing 
layer. Drug -in -adhesive patch may be single layer or multi layer. The multi layer system is 
different from single layer in that it adds another layer of drug-in-adhesive, usually 
separated by a membrane.  
 Some examples of suitable pressure sensitive adhesives are polysiloxanes, 
polyacrylates and polyisobutylene. These pressure sensitive adhesives are hydrophobic in 
nature and are prepared as solutions of polymer dissolved in organic solvents. Hence, this 
type of system is preferred for hydrophobic drugs as it is to be incorporated into organic 
solvent based hydrophobic adhesive43. Rachel et al., (2004) prepared drug in adhesive 
patches of green tea extract and it was observed that major catechins and caffeine extracted 
from green tea were successfully delivered transdermally from drug-in-adhesive patches44. 
Kannikkanan et al., (2004) prepared and evaluated monolithic drug in adhesive type 
transdermal patches of melatonin and used eudragit E100 as adhesive polymer45. Lake and 
Pinnock (2000) proved that once a week drug in adhesive patch of estrogen is more patient 
compliant as compared to twice a week reservoir patch. Characteristics of drug in adhesive 
patch may account for improved patient compliance due to ease of remembering once 
weekly patch application, improved cosmetic acceptance and better adhesion46. Examples of 
marketed preparations of drug-in-adhesives patches are Climara®, Nicotrol® and Deponit®. 
Design of this system is shown in Figure 10.  
 
Fig: 10 Drug in adhesive type transdermal patch 
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Polymers for transdermal drug delivery systems47  
  Transdermal drug delivery technology represents one of the most rapidly    
advancing areas of novel drug delivery. This growth is catalyzed by developments in the 
field of polymer science.  
Pharmaceutical polymers form an integral part of the transdermal drug delivery 
systems. Typically polymeric layers may be used as the protective outer covering to protect 
the dosage form from external damage. There may be a layer in which the drug is dispersed / 
dissolved within a polymeric matrix, which acts to control drug release to the skin. In 
addition, there is an adhesive layer, which is used to locate and maintain the dosage form at 
the site of application. Alternatively, in certain designs, the adhesive layer may additionally 
operate as the drug reservoir. 
The major parts of TDS are a controlled release device composed of polymers, the 
drug, excipients and enhancers, a fastening system, usually a pressure-sensitive adhesive 
(PSA), to fix the device to the skin, and a hermetically sealed package composed of 
impervious film. Advances in transdermal drug delivery technology have been rapid because 
of the. Sophistication of polymer science which now allows incorporation of polymers in 
TDS in adequate quantity. The importance of polymer selection can be appreciated more if 
one considers the different design criteria which must be fulfilled 
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 POLYMER USEFUL FOR TRANSDERMAL DEVICES47 
Table-1       
POLYMERS ROLE 
Natural polymers 
Gelatin 
Sodium alginate 
Gum Arabic 
Starch 
Gum tragacanth 
Protein 
Casein 
Natural rubber 
 
Base,adhesives 
Base,adhesives 
Base,adhesives 
Base,adhesives 
Adhesives 
Adhesives 
Adhesives 
Base,adhesives 
Semisynthetic polymers 
Cellulose acetate phthalate 
Methyl and ethyl cellulose 
Nitrocellulose 
Hydroxy Propyl Cellulose 
 
 
Base,adhesive 
 
 
Synthetic elastomers 
Polybutadiene 
Polyisoprene 
Polysiloxane 
Silicone rubber 
 
 
Base with adhesive 
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Synthetic polymers 
Polyvinyl alcohol 
Polypropylene 
Polyethylene 
polystyrene 
Polyurethane 
Polyvinyl pyrrolidone 
Polymethyl methacrylate 
Polyvinyl acetate 
Polyhydroxy ethyl methcrylate 
Polyvinyl chloride 
polyacrylamide 
Polyethylene glycol 
Polyester 
Polyamide polymer 
Epoxy ethyl vinyl acetate 
 
Aqueous base,adhesive, baking membrane 
Linear,co-adhesive 
Co adhesive 
Foam,backing 
Aq.base,adhesive 
linear 
base 
linear 
 
 
base, adhesive 
base,adhesive 
Base,adhesive 
Base,Linear,baking,foam 
Foam 
 
Innovation in Transdermal Technology  
          The conventional passive means of applying drugs to skin include the use of vehicles 
such as ointments, creams, gels and patch technology. More recently, such dosage forms 
have been developed and/or modified in order to enhance the driving force of drug diffusion 
(thermodynamic activity) and/or increase the permeability of the skin. These approaches 
include the use of penetration enhancers, super saturated systems, hyaluronic acid, prodrugs, 
liposomes and other vesicles. 
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However, the amount of drug that can be delivered using these methods is still 
limited since the barrier properties of the skin are not fundamentally changed and as such, 
with the exception of patches, the majority are used to treat localized skin diseases where 
systemic absorption is not required. Thus, while new passive technologies typically offer an 
improvement in dose control, patient acceptance and compliance compared to more 
traditional semisolid formulations, they do not have the potential to widen the applicability 
of transdermal drug delivery unlike active transdermal drug delivery technologies.48  
RECENT TECHNIQUES FOR ENHANCING TRANSDERMAL DELIVERY 49:  
 
 
 
 
 
 
 
  Fig- 11 
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techniques 
for enhancing 
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Structured-based 
 
 
 
Electrically based 
 
 
 
Velocity-based 
 
 
 
Others 
 
 
Micro needles 
Macro flux 
MDTS 
 
Iontophoroses 
Ultra sound 
Electro poration 
Electro osmosis 
Photo mechanical 
waves 
 
 
Power jet 
Needle free 
injection  
 
 
Transferosomes 
Skin abrasion 
Heat 
Laser radiation 
Magnetophoresis 
Medicated tattoos 
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Active Methods 
              A rich area of research over the past 10 to 15 years has been focused on developing 
transdermal technologies that utilize mechanical energy to increase the drug flux across the 
skin by either altering the skin barrier (primarily the stratum corneum) or increasing the 
energy of the drug molecules. Recent progress in active transdermal drug delivery 
technologies has occurred as a result of advances in precision engineering (bio-engineering), 
computing, chemical engineering and material sciences, which have all helped to achieve 
the creation of miniature, powerful devices that can facilitate the generation of a required 
clinical response.  
            These so-called “active” transdermal technologies include iontophoresis, 
electroporation, microneedles, abrasion, needle-less injection, suction, stretching, 
ultrasound, magnetophoresis, radio frequency, lasers, photomechanical waves, and 
temperature manipulation. Some most commonly employed techniques include the 
following
.  
Iontophoresis 
              This method involves the application of a low level electric current either directly to 
the skin or indirectly via the dosage form in order to enhance permeation of a topically 
applied therapeutic agent. Products have already reached the US market using iontophoresis. 
e.g., recently, FDA approved a pre-filled, pre-programmed iontophoric device for sale in the 
United States. This product, called LidositeTM, delivers lidocaine and epinephrine to intact 
skin to provide local anesthesia for superficial dermatological procedures. 
Electroporation 
             This method involves the application of high voltage pulses to the skin which has 
been suggested to induce the formation of transient pores. High voltages (Z100 V) and short 
treatment durations (milli seconds) are most frequently employed. Other electrical 
parameters that affect delivery include pulse properties such as waveform, rate and number. 
The technology has been successfully used to enhance the skin permeability of molecules 
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with differing lipophilicity and size (i.e. small molecules, proteins, peptides and 
oligonucleotides) including biopharmaceuticals with molecular weights greater that 7 KDA.  
            As electroporation improves the diffusion of such a wide range of compounds, it is 
thought that the pores created in the superficial layers of the skin are directly responsible for 
the increase in skin permeability. Genetronics, Inc. has developed a prototype 
electroporation transdermal device, which has been tested with various compounds with a 
view to achieving gene delivery, improving drug delivery and aiding the application of 
cosmetics.  
Microneedle-based Devices 
A new area of intense transdermal research and development is the development of 
devices that create micropores in the stratum corneum, the top most layer of the skin that 
serves as the greatest barrier to drug diffusion. Such devices include micro structured arrays, 
sometimes called microneedles, that when applied to the skin, painlessly create micropores 
in the stratum corneum without causing bleeding. These micropores offer lower resistance to 
drug diffusion than normal skin without micropores. The very first microneedle systems, 
described in 1976, consisted of a drug reservoir and a plurality of projections (microneedles 
50 to 100 mm long) extending from the reservoir, which penetrated the stratum corneum and 
epidermis to deliver the drug. More recently, as a result of the rapid advancement in 
microfabrication technology in the last 10 years, numerous cost-effective methods of 
producing microneedle devices have been developed. The ALZA Corp. has recently 
commercialized a microneedle technology named Macroflux which can either be used in 
combination with a drug reservoir or by dry coating the drug on the microprojection array; 
the latter being better for intracutaneous immunization.  
Skin Abrasion 
             The abrasion technique involves the direct removal or disruption of the upper layers 
of the skin to facilitate the permeation of topically applied medicaments. Some of these 
devices are based on techniques employed by dermatologists for superficial skin resurfacing 
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(e.g. microdermabrasion) which are used in the treatment of acne, scars, hyperpigmentaion 
and other skin blemishes.  
Microscissuining is a process which creates micro channels in the skin by eroding the 
impermeable outer layers with sharp microscopic metal granules. Carlisle Scientific is 
currently in the process of developing a pen-like handheld device called the microscissioner.  
              In addition, Med Pharm Ltd. has recently developed a novel dermal abrasion device 
(D3S) for the delivery of difficult to formulate therapeutics ranging from hydrophilic low 
molecular weight compounds to biopharmaceuticals. In vitro  data has shown that the 
application of the device can increase the penetration of angiotensin into the skin 100-fold 
compared to untreated human skin. This device is non-invasive and histological studies on 
human skin show that the effects on the stratum corneum are reversible and non-irritating.  
Needle-less Injection  
                This is reported to involve a pain-free method of administering drugs to the skin. 
Over the years, there have been numerous examples of both liquid (Ped-O-Jet, Iject, 
Biojector2000, Medi-jector and Intraject) and powder (PMED device formerly known as 
Powderject injector) systems. The latter device has been reported to successfully deliver 
testosterone, lidocaine hydrochloride and macromolecules such as calcitonin and insulin.  
              This method of administering drugs circumvents issues of safety, fear and pain 
associated with the use of hypodermic needles. Transdermal delivery is achieved by firing 
the liquid or solid particles at supersonic speeds through the outer layers of the skin using a 
suitable energy source. The PMED device consists of a Helium gas cylinder, drug powder 
sealed in a cassette made of plastic membrane, a specially designed convergent-divergent 
supersonic nozzle and a silencer to reduce the noise associated with the rupturing of the 
membrane when particles are fired.  
             The mechanism involves forcing compressed gas (Helium) through the nozzle, with 
the resultant drug particles entrained within the jet flow reportedly traveling at sufficient 
velocity for skin penetration. An essential difference between administration of a DNA 
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vaccine by needle injection or by PMED is the efficiency with which the administered DNA 
generates the encoded protein for presentation on the surface of antigen-presenting cells 
(APCs). Using PMED, it is possible to deliver the DNA directly to the intracellular 
compartment of cells within the epidermis, and because the epidermis is rich in APCs, 
significant numbers can potentially be targeted with each administration. This is supported 
by non-clinical studies in pigs that have included histological examination of PMED 
administration sites.  
Ultrasound (sonophoresis and phonophoresis) 
This technique involves the use of ultrasonic energy to enhance the transdermal 
delivery of solutes either simultaneously or via pre-treatment and is frequently referred to as 
sonophoresis or phonophoresis. The SonoPrep device (Sontra Medical Corp.) uses low 
frequency ultrasound (55 KHz) for an average duration of 15 seconds to enhance skin 
permeability. This battery-operated, handheld device consists of a control unit, ultrasonic 
horn with control panel, a disposable coupling medium cartridge, and a return electrode. 
Laser Radiation 
             This method involves direct and controlled exposure of a laser to the skin which 
results in the ablation of the stratum corneum without significantly damaging the underlying 
epidermis. Removal of the stratum corneum using this method has been shown to enhance 
the delivery of lipophilic and hydrophilic drugs. A handheld portable laser device has been 
developed by Norwood Abbey Ltd. (Victoria, Australia), which in a study involving human 
volunteers, was found to reduce the onset of action of lidocaine to 3 to 5 minutes, while 60 
minutes was required to attain a similar effect in the control group. The Norwood Abbey 
system has been approved by the U.S. and Australian regulatory bodies for the 
administration of a topically-applied anaesthetic. Laser systems are also being developed to 
ablate the stratum corneum from the epidermal layer. As with microneedles, the ablated 
regions offer lower resistance to drug diffusion than non-ablated skin. One company has 
recently received FDA approval to market this device with a lidocaine cream Dispenser for 
Transdermal Patches. 
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Magnetophoresis, which is still in the research phase, enhances skin permeability by 
applying a magnetic field.  
TRANSDERMAL MARKET  
 The market for transdermal products has been in a significant upward trend that is 
likely to continue for the foreseeable future. An increasing number of TDD products 
continue to deliver real therapeutic benefit to patients around the world. More than 35 TDD 
products have now been approved for sale in the US. 
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Table -2 
 
 
Product 
name 
Drug Manufacturer Indication 
Alora Estradiol TheraTech/Proctol and Gamble Postmenstrual syndrome 
Androderm Testosterone TheraTech/GlaxoSmithKline Hypogonadism in males 
Catapres-TTS Clonidine Alza/Boehinger Ingelheim Hypertension 
Climaderm Estradiol Ethical Holdings/Wyeth-Ayerest Postmenstrual syndrome 
Climara Estradiol 3M Pharmaceuticals/Berlex Labs Postmenstrual syndrome 
CombiPatch Estradiol/Norethindrone Noven , Inc./Aventis Hormone replacement therapy 
Deponit Nitroglycerin Schwarz-Pharma Angina pectoris 
Duragesic Fentanyl Alza/Janssen Pharmaceutica Moderate/severe pain 
Estraderm Estradiol Alza/Norvatis Postmenstrual syndrome 
Fematrix Estrogen Ethical Holdings/Solvay Healthcare  Postmenstrual syndrome 
FemPatch Estradiol Parke-Davis Postmenstrual syndrome 
Habitraol Nicotine Novartis Smoking cessation 
Minitran Nitroglycerin 3M Pharmaceuticals Angina pectoris 
Nicoderm Nicotine Alza/GlaxoSmithKline Smoking cessation 
Nicotrol Nicotine 
Cygnus Inc./McNeil Consumer 
Products, Ltd. 
Smoking cessation 
Nitrodisc Nitroglycerin Roberts Pharmaceuticals Angina pectoris 
Nitro-dur Nitroglycerin Key Pharmaceuticals Angina pectoris 
Nuvelle TS Estrogen/Progesterone Ethical Holdings/Schering Hormone replacement therapy 
Ortho-Evra Norelgestromin/estradiol Ortho-McNeil Pharmaceuticals Birth control 
Prostep Nicotine Elan Corp./Lederle Labs Smoking cessation 
Testoderm TTS Testosterone Alza Hypogonadism in males 
Transderm Scop Scopolamine Alza/Norvatis Motion sickness 
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 The pie diagram given below shows that Fentanyl and nitroglycerine are the drugs 
most popularly marketed using transdermal patches. 
 
 
Fig-12 
 
Table-3: US Sales of Select Prescription Transdermal 
Product
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Table-4: Over-the-Counter Patch Products Currently Marketed in US50 
 
 
 
The Future of TDDS - New Systems 
 Several exciting 'active' transdermal drug delivery systems are also on the 
horizon. Systems using external stimuli to drive the drug into the skin will offer rate-
controlled, on-demand delivery of those drugs with a larger molecular weight which until 
now were not deliverable by passive transdermal patches. For example, iontophoresis uses a 
miniature battery to establish an electrical potential between the adhesive and the skin in a 
TDD patch, which uses a conductive adhesive. 
 
               A mild electrical current delivers an ionically charged drug into the skin. Currently, 
reverse iontophoresis has been developed for use as a diagnostic tool in the medical 
diagnostics industry for blood glucose monitoring, attracting fluid out of the skin that can be 
analysed. Sonophoresis, which uses ultrasound waves, is also being tested. A portable 
device emits sound waves through a patch attached to the device for painless delivery of a 
drug through the skin. The adhesive used must be able to withstand the effects of the sound 
waves. 
 
              Yet another method is electroporation, which uses electric current to change the 
surface properties of the skin, creating channels of low transmission-resistance and thereby 
accelerating drug delivery. 
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              Further, buccal or transmucosal patches have been designed to be placed in the 
mouth to deliver a drug through the mucous membranes. This technique will allow much 
higher drug flux and enable large, higher molecular weight drugs to be administered 
transdermally. The challenge for adhesive manufacturers is to develop an adhesive that 
adheres to wet surfaces on the interior of the mouth and will not dissolve in the presence of 
an aqueous environment. 
In the future, we can expect advances in passive transdermal patches to include: 
 Extended wear patches with stronger cohesion properties to remain at a fixed point 
on the skin without movement 
 Bi-phasic drug delivery profiles such as time-delayed or time moderated delivery 
 Smaller, more aesthetically acceptable patches with increased solubility of the drug 
in the adhesive for a higher diffusion rate 
 Generic drug patches 
 Combinational drug patches, such as nicotine with an anti-irritant that delivers more 
than one drug, each with a different size molecule and potentially different 
therapeutic levels. 
               The adhesive manufacturers who are succeeding in the TDDS market are those that 
have invested in partnerships with pharmaceutical companies. These companies require the 
adhesive manufacturers to be deeply involved in the product development process, 
conducting research, testing and materials qualification for adhesive formulation and 
ultimately. 
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4.0 REVIEW OF LAMIVUDINE 
 Formulation and Evaluation of Ethosomes for Transdermal Delivery of 
Lamivudine to investigate the mechanism for improved intercellular and intracellular drug 
delivery from ethosomes using visualization techniques and cell line study, and concluded 
that the visualization study indicate that ethosomal formulation affected the normal 
histology of skin by producing lipid perturbation and increasing the intercellular lipid 
lamellae space of the SC51. 
 
Preparation and characterization of Lamivudine microcapsules using various 
cellulose polymers the  study was to prepare and evaluate microcapsules for the controlled 
release of lamivudine using various cellulose polymers and concluded that the release 
kinetics data and characterization studies indicate that drug release from microcapsules was 
diffusion – controlled and that the microcapsules were stable52. 
 
Design and Study of Lamivudine Oral Controlled Release Tablets the study was 
to design oral controlled release matrix tablets of lamivudine using hydroxypropyl 
methylcellulose (HPMC) as the retardant polymer and to study the effect of various 
formulation factors such as polymer proportion, polymer viscosity, and compression force 
on the in vitro release of drug, and concluded that the CR matrix tablets of LAM 
conforming to good quality were prepared using HPMC by the wet granulation method. 
Release rate of the drug from the matrix tablets was dependent on proportion as well as 
viscosity of HPMC used, which release 20%to 30%of drug in the first hour and extend the 
release up to 16 to 20 hours, can overcome the disadvantages associated with conventional 
tablet formulations of LAM53. 
 
Lamivudine Liposomes for Transdermal Delivery - Formulation, 
Characterization, Stability and In vitro  Evaluation to study the   preparation of 
liposomes of Lamivudine by thin film hydration and their potential for transdermal drug 
delivery has been evaluated in vitro ,and concluded that formulated 3TC liposomes  were 
stable and have shown appreciably controlled skin permeation as well as minimal retention 
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of drug molecules in the skin. Also by achieving controlled release of lamivudine across the 
skin, it is possible to achieve a reduction in dose, while maintaining the required drug 
concentration5. 
 
Dissolution test for lamivudine tablets: Optimization and statistical analysis to 
study the comparison of different methods for dissolution test used by five different 
manufacturer laboratories of lamivudine tablets is made, evaluated, and discussed…and 
concluded the methods and conditions established by the manufacturer laboratories, all 
batches presented equivalent results to the reference product. However, when the method 
and criteria proposed by this work were used, smaller DR% values were observed for 
batches C1, C2, and C3 when compared to those of reference, and therefore could not be 
considered equivalent54. 
 Preparation, Evaluation and in vitro  – in vivo Correlation (IVIVC) study of 
Lamivudine Loaded Microspheres to study the establishment of an Invitro-Invivo 
correlation of prepared sustained release microspheres and compared with conventional 
Lamivudine tablet after administrating orally to New Zealand white rabbit species..and 
concluded that all the formulated microspheres showed identical pharmacological effect in 
comparison to standard lamivudine tablet. Parameters like dissolved fraction absorbed, DT 
vs. MRT and T85% revealed a significant in vitro- in vivo correlation55. 
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5.0 DRUG PROFILE 
                                                  LAMIVUDINE56,57,58 
 
Chemical Name      : (2R, cis)-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-         
                                     pyrimidine - 2-one.   
Molecular Formula    : C8H11N3O3S 
Molecular Weight      : 229.3  
Physical properties    : white to off-white crystalline solid. 
Solubility                    : Freely soluble in water. 
Melting point             :  160-1620c 
Structure                   :    
 
Mechanism of action   
         Lamivudine is a selective inhibitor of HIV-1 and HIV-2 replication, including 
zidovudine-resistant clinical isolates of the human immunodeficiency virus (HIV). 
Lamivudine is a synthetic nucleoside analogue. Intracellularly, lamivudine is phosphorylated 
to its active 5′-triphosphate metabolite, lamivudine triphosphate, 3TC-TP. Incorporation of 
the monophosphate form into viral DNA by HBV reverse transcriptase results in DNA chain 
termination. 3TC-TP also inhibits the RNA- and DNA-dependent DNA polymerase 
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activities of HIV-1 reverse transcriptase (RT). 3TC-TP is a weak inhibitor of mammalian α, 
β, and γ-DNA polymerases.    
 
Clinical Uses 
 
Lamivudine is indicated for the treatment of HIV when used in combination with 
other antiretroviral agents.A lower dose than that used to treat HIV is approved for the 
treatment of HBV. Although lamivudine initially improves histological and biochemical 
measures of hepatic function and reduces HBV DNA to below the limits of detection, 
withdrawal of the drug usually results in disease recurrence. Resistance appears in up to one 
third of patients after 1 year of treatment. 
 
Pharmacokinetics  
Adults   
Onset of action              : Prompt  
 Time to peak, serum     :  1 hour  
 Oral Bioavailability              :  80%   
 Half life elimination      :  5-7 hours (oral)    
 Excretion                        :  Urine. 
 Protein binding                :  less than 36% 
 Renal excretion                :  70% 
 Volume of distribution     : 1.3 L/kg 
 Plasma concentration        :  1.4 µg/ml 
 
Drug interactions   
 Lamivudine and zalcitabine may inhibit the intracellular phosphorylation of one 
another. Therefore, use of lamivudine in combination with zalcitabine is not recommended.   
Pregnancy : No evidence of teratogenicity due to lamivudine was observed .     
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Nursing Mothers: Lamivudine is also excreted in human milk. Samples of breast milk 
obtained from 20 mothers receiving lamivudine monotherapy (300 mg twice daily) or 
combination therapy (150 mg lamivudine twice daily and 300 mg zidovudine twice daily) 
had measurable concentrations of lamivudine. Because of the potential for serious adverse 
reactions in nursing infants, mothers should be instructed not to breastfeed if they are 
receiving lamivudine.  
 
ADVERSE REACTIONS   
Non-site Specific            :  Malaise and fatigue, Fever or chills   
Ear, Nose, and Throat   :  Ear, nose and throat infections, Sore throat    
Gastrointestinal              :  Nausea and vomiting, abdominal discomfort and pain,   
Musculoskeletal              :  Myalgia, Arthralgia, Neurological, Headache   
  
Paediatric Patients with HIV Infection: In early open-label studies of lamivudine in 
children with HIV, peripheral neuropathy and neutropenia were reported, and pancreatitis 
was observed in patients.   
 
DOSAGE AND ADMINISTRATION  
Adults: The recommended oral dose of lamivudine is 150mg (twice daily) for treatment of 
HIV in adults.  
Pediatric Patients: The recommended oral dose of lamivudine for pediatric patients 2 to 17 
years of age with HIV is 3 mg/kg once daily up to a maximum daily dose of 100 mg. 
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6.0 POLYMER PROFILE 
HYDROXY PROPLY METHYL CELLULOSE 59,60 
           It is mixed alkyl-hydroxy alkyl cellulose ether and may be regarded as the propylene 
glycol ether of methyl cellulose. 
BP           :      Hypromellose 
USP       :    Hydroxy propyl methyl cellulose 
Chemical name              :    Cellulose, 2- hydroxypropyl methylether. 
Empirical formulae       :    Hydroxy propyl methyl cellulose is partly O-methylated and  
     O-(2-hydroxypropylated) cellulose. It is available in several  
     Grades which vary in viscosity and extend of substitution  
Structure                         
 
where R is H, CH3, or CH3CH(OH)CH2 
Molecular weight             :    4000 mol. daltons 
SYNONYM                          :      HYPROMELLOSE 
Trade name                      :    Methocel 
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Solubility                           :     Methocel soluble in cold water, forming a viscous  
    colloidal solution; practically insoluble in chloroform, 
    ethanol 95% and ether, but soluble in mixtures of  
    ethanol and dichloro methane, mixtures of methanol 
    and dichloromethane, and mixtures of water and  
    alcohol.   
Description                        :     An odorless and tasteless, white or creamy-white  
     fibrous(or) granular powder. 
Density                             :    Bulk      :  0.341 g/cm3  
                                          :      Tapped  :  0.557 g/cm3 
                                           :    True       :  1.326 g/cm3 
Specific gravity           :     1.26 g/cm3 
Viscosity                           :     Low viscosity grade 
Grade                                :     HPMC K 4M 
pH                                      :    5.5–8.0 for a 1% w/w aqueous solution. 
Stability                             :   Very stable in dry conditions. Solutions are stable at 
    pH 3-11 
Functional category         :    Coating agent; film former; rate controlling polymer 
     for Sustained release; stabilizing agent; viscosity- 
     increasing agent; tablet binder.  
Applications             :    1) In oral products, hypromellose is primarily used as a 
  tablet Binder, in film-coating, and as a matrix for use 
  in extended release tablet formulations. 
  2)  It  is widely used in oral and topical pharmaceutical 
  formulation. 
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                                                3) Concentrations between 2% and 5% w/w may be  
  used as abinder in either wet- or dry-granulation  
  processes.  
                                                4) High-viscosity grades may be used to retard the  
 release of drugs from a matrix at levels of 10–80%  
 w/w in tablets and capsules. 
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ETHYL CELLULOSE61 
 
Chemical name               :   Cellulose ethyl ether. 
Structure                         : 
 
Functional Category       :    Coating agent; flavoring fixative; tablet binder; tablet 
     filler; Viscosity - increasing agent. 
Solubility                         : Soluble in chloroform, ethanol (95%), ethyl acetate,     
  methanol, and toluene. Practically insoluble in  
  glycerin, propylene glycol, and water.                                      
Description                :     Ethylcellulose is a tasteless, free-flowing, white to 
 light tan colored powder. 
Bulk density                    :      0.4 g/cm3 
Viscosity                           :     7 to 100 mPa s  for a 5% w/v solutions 
Specific gravity                : 1.12–1.15 g/cm3 
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Stability                          :     Ethylcellulose is a stable, slightly hygroscopic  
     material. It is chemically resistant to alkalis, both  
     dilute and concentrated, and to salt solutions, although 
     it is more sensitive to acidic materials than are  
     cellulose esters. 
Incompatibility                : Incompatible with paraffin wax and microcrystalline 
   wax. 
Safety                                :     Ethylcellulose is widely used in oral and topical     
                                                 Pharmaceutical formulations. It is also used in food    
                                                 products. 
Application                 :  1) The main use of ethylcellulose in oral 
 formulations is as a hydrophobic coating  agent for 
 tablets and granules. 
 2) Ethylcellulose coatings are used to modify the 
 release of a drug, to mask an unpleasant taste, or to 
 improve the stability of a formulation; for example, 
 where granules are coated with ethylcellulose to inhibit 
 oxidation. 
 3) Modified-release tablet formulations may also be      
 produced using ethylcellulose as a matrix former. 
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SPAN-80 
Synonyms: Sorbitan Monolaurate           
Empirical Formula: C18H34O6  
Molecular Weight: 346 
Structural formula: 
 
 
 
 
 
 
R1 = R2 = OH, R3 = R  for sorbitan monoesters 
where R =  (C11H23)COO for laurate 
 
Functional category: Emulsifying agent; nonionic surfactant; solubilizing agent; wetting 
and dispersing/suspending agent. 
 
Application in pharmaceutical formulation 
 Span 80 are widely used in cosmetic, food products, and pharmaceutical 
formulations as lipophilic non-ionic surfactants. 
 They are mainly used in pharmaceutical formulations as emulsifying agent in the 
preparation of creams, emulsion, and ointments for topical application. 
 When used alone span 80 produce stable water –in-oil emulsion and micro emulsion. 
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Description: Sorbitan esters occur as cream to amber-colored liquids or solid with a 
distinctive odor and taste. Span 80 occurs as yellow viscous liquid. 
 
Typical properties            
Table- 5 
                                       
 
 
 
 
Stability and storage condition 
               Gradual soap formation occurs with strong acid or bases; sorbitan esters are stable 
in weak acid or bases. Sorbitan esters should be stored in a well- closed container in a cool, 
dry place. 
  
Safety 
            They are generally regarded as non-toxic and non-irritant materials. However, there 
have been occasional reports of hypersensitive skin reaction following the topical 
application of product containing sorbitan esters. When heated to decomposition the sorbitan 
esters emit acrid smoke and irritating fumes. 
 
 
 
Permeation 
enhancer 
Density (g/cm3) HLB value Viscosity(mPs) 
Span 80 1.01 8.6 2970-4080 
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7.0 OBJECTIVE OF THE STUDY 
 Study has been carried to provide an Anti-viral drug in transdermal delivery 
system. The main object is to evaluate the feasibility of sustained controlled delivery of 
therapeutically effective amount of nucleoside reverse transcriptase inhibitors in Matrix type 
transdermal delivery system. 
 The nucleoside reverse transcriptase inhibitors have become the first-line therapy 
in treating HIV and HBV patients.. 
 The transdermal drug delivery system has gained popularity over the past few 
decades. The major penetration pathway of drug molecules through the stratum corneum of 
intact human skin is by diffusing through the lipid envelopes of the skin cells. 
 Lamivudine was selected among the nucleoside reverse transcriptase inhibitors 
due to the molecular size, therapeutic dose, and half-life and to have a chronic treatment for 
the disease. 
 Lamivudine is a nucleoside reverse transcriptase inhibitor used in HIV and HBV 
have been selected for the study to be formulated into a transdermal delivery system. 
Following oral administration, the elimination half-life is 6.1 hrs; the absolute bio-
availability is approximately 80% due to first-pass metabolism and controlled release of the 
drug is not maintained. So, an alternative route like TDDS was chosen to deliver the drug to 
the systemic circulation in a controlled manner. 
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8.0 PLAN OF THE WORK 
       It was planned to carry out the study in the sequences below. 
 
1. The Compatibility study of drug & polymer by using FT-IR absorption spectra. 
2. Preparation of standard curve by using phosphate buffer PH 7.4. 
3.   Fabrication of Matrix transdermal patches of Lamivudine by using different ratios of   
 hydroxy propyl methyl cellulose (HPMC) and Ethyl cellulose (EC) as polymers. 
4. Evaluation of transdermal patches 
• Physico-chemical evaluations 
1. Thickness of the patch 
2. Folding  endurance 
3. Percentage of moisture absorbed 
4. Percentage of moisture lost 
5. Water vapor transmission rate 
6. Drug content uniformity 
• Stability studies. 
• In-vitro skin permeation studies.. 
• Skin irritation test.. 
• Statistical analysis by ANOVA  
• In-vivo studies. 
• In-vitro/In-vivo correlation. 
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9.0 MATERIALS AND INSTRUMENTS 
       Drug and its supplier 
Table-6 
Drug Supplier /Manufacture 
 
Lamivudine  
 
 
Aurobindo Pharma  Pvt Ltd., Hyderabad ,  
Andhra Pradesh, India 
 
 
     Materials and their supplier 
Table-7 
Material 
 
Supplier /Manufacture 
Hydroxy propyl  methyl cellulose- E 15 LV 
 
Loba  Chemie Pvt. Ltd., Mumbai. 
Ethyl cellulose 
 
Loba  Chemie Pvt. Ltd., Mumbai. 
Glycerol 
 
Spectrum Reagents and Chemicals Pvt. 
Ltd., Cochin. 
Span  80 
 
Loba  Chemie Pvt. Ltd., Mumbai. 
Choloroform 
 
Loba  Chemie Pvt. Ltd., Mumbai. 
Distilled water 
 
Distillation Unit., Banglore. 
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 Instruments and their supplier 
 
Table-8 
Instrument Supplier /Manufacture 
Digital Weighing balance Shimadzu Corporation, Japan. 
Dial caliper Mitutoyo corporation, Japan 
pH meter Hanna instruments, Italy 
Orbitek shaker Scigenics Biotech Pvt. Ltd., Chennai 
Franz diffusion cell (60 ml) Universal Scientific Co., Coimbatore 
UV/VIS spectrophotometer Perkin Elmer, Lambda 25 
FTIR spectrophotometer Perkin Elmer, Spectrum RXI 
Stability Chamber Inlab Equipments, Chennai 
HPLC spectrophotometer Perkin Elmer, Spectrum RXI 
Remi CPR-24 centrifuge Remi instruments, Mumbai 
Magnetic stirrer Bio-Craft Scientific Systems Pvt. Ltd., Agra 
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10.0 METHODS 
 
10.1 COMPATIBILITY STUDY OF DRUG AND THE POLYMER80  
FTIR absorption spectra: 2 mg of the substance being examined was triturated with 
300mg to 400mg of finely powdered and dried potassium bromide. This quantity was 
usually sufficient to give a disc of 13 mm diameter and a spectrum of suitable intensity. The 
mixture was grinded carefully, spread it uniformly in a suitable die, and submit in a vacuo to 
a pressure of about 800 Mpa (8t.cm-2). The same product was repeated for the polymer and 
the physical mixture of drug and the polymers. 
 
10.2 REAGENTS PREPRATION 
Preparation of phosphate buffer pH 7.4 62 
 Place 50.0ml of 0.2M potassium dihydrogen phosphate in a 200ml volumetric flask, 
add the specified volume of 39.1 ml of 0.2M sodium hydroxide and then add water to make 
up the volume. 
 
0.2M potassium dihydrogen phosphate  
Dissolve 27.218g potassium dihydrogen phosphates in distilled water and dilute to 
1000ml with distilled water. 
 
0.2M sodium hydroxide solution 
 Dissolve 8g of sodium hydroxide in distilled water and dilute to 1000ml with 
distilled water. 
 
10.3 PREPARATION OF STANDARD CURVE5 
Stock solution 
100mg of Lamivudine was dissolved in 100ml of pH 7.4 phosphate buffer, so as to 
get a solution 1000µg/ml concentration. 
 
Standard solution 
10 ml of stock solution was made to 100ml with pH 7.4 thus giving a concentration 
of 100 µg/ml. Aliquot of standard drug solution ranging from 1ml to 8ml were transferred in 
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to 10ml volumetric flask and were diluted up to the mark with pH 7.4 phosphate buffer. 
Thus the final concentration ranges from 10-60 µg/ml. Absorbance of each solution was 
measured at 270 nm against pH 7.4 phosphate buffer as a blank. A plot of concentrations of 
drug versus absorbance was plotted. 
 
Normal saline 
                       Dissolve   0.9% w/v sodium chloride in 100 ml of purified water. 
 
10.4 DOSE DESIGNING81 
 On the basis of pharmacokinetic parameters of Lamivudine, the drug delivery 
rate through skin required to achieve effective plasma concentration was calculated using 
the equation, 
 Kp = Q/t = (Cplasma) ss. Kel Vd 
Where, Q/t (or) Kp is the drug input rate 
            (Cplasma)ss is the drug level at steady state 
            Kel is elimination rate constant 
            Vd is the volume of distribution of drug 
In calculation of dose designing for the formulation of transdermal drug delivery system, the 
skin/drug partitioning and polymer/drug partitioning are play major role. 
 
Table-9    
(Cplasma)ss 
(µg/L) Kel (h)
-1
 Vd (L/kg) Kp (mg/hr) Total drug/24hrs (mg) 
1.4 0.1136 1.3 0.2067 
 
4.96 mg. ≅ 5.0 mg 
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10.5 FABRICATION OF TRANSDERMAL PATCHES 63,64,65,66 
 Matrix patches were casted on glass mould by solvent casting method. Four types of 
polymer patches were prepared. First two formulations were prepared by  using HPMC 
alone having drug & polymer ratio 1:2.5, 1:5 using water as a solvent and the next 
formulations were formulated  using  EC having drug & polymer ratio 1:2.5, 1:5 using 
chloroform as a solvent with Span 80 (1%), as permeation enhancer, Glycerol (3%) was 
used as a plasticizer. The films were cast onto a suitably designed and fabricated glass 
mould and then dried in hot air oven at 400C for six hours . The films were removed by 
using sharp blade by inserting along the edges of the film. The dried films were wrapped in 
aluminium foils and stored in a closed container in cool place away from light. 
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Table-10: Fabrication of Lamivudine Matrix Transdermal patches of 3.14 Sq cm 
  
 
S. No Ingredients 
F1 W 
(1:2.5) 
F2 W 
(1:5) 
F3 W 
(1:2.5) 
F4 W 
(1:5) 
FPE1  
(1:2.5) 
FPE2  
(1:5) 
FPE3  
(1:2.5) 
FPE4 
(1:5) 
1 Drug (Lamivudine in 
mg) 5.0 5.0 5.0 5.0 5.0 5.0 5.0 5.0 
2 
Hydroxy propyl 
methyl  cellulose 
(mg) 
12.5 25 -- -- 12.5 25 -- -- 
3 Ethyl cellulose (mg) -- -- 12.5 25 -- -- 12.5 25 
4 Span-80 -- -- -- -- 1% 1% 1% 1% 
5 Glycerol 3% 3% 3% 3% 3% 3% 3% 3% 
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10.6 PHYSICOCHEMICAL EVALUATIONS OF THE TRANSDERMAL 
PATCHES 64, 67,68,69,70  
Thickness of the patch 
 Thickness of the patch was measured by using ‘Dial gauge’ in mm. 
Folding endurance 
 The folding endurance was measured manually for the prepared film. A strip of film 
was cut evenly and folded at the same place till it broke. The number of times the film could 
be folded at the same place without breaking gave the exact value of folding endurance. 
Percentage of moisture absorbed 71 
 To check the physical stability of the film in high humidity condition, accurately 
weighed film were placed in a desiccators containing saturated solution of Aluminium 
chloride (79.5% relative humidity) for 3 days. The films were reweighed and percentage 
moisture absorption was calculated using the formula. 
        Percentage moisture absorption       =    Final weight - Initial weight  
 x 100 
                                                                                     Initial weight 
Percentage of moisture lost71 
 To check the extent of moisture loss from freshly prepared film, accurately weighed 
films were placed in a desiccator containing fused anhydrous Calcium chloride for 72 hrs. 
After 72 hrs, the films were reweighed and percentage moisture loss was calculated using 
the formula.      
            Percentage moisture lost     = Initial weight - Final weight x 100 
                                                                        Initial weight 
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Water vapor transmission68, 72, 73: 
 It is defined as the quantity of moisture transmitted through unit area of film in unit 
time. For the study of WVT rate, vials of equal diameter were used as transmission cells 
(approximately 5 ml vials). These cells washed thoroughly and dried in an oven. 
Approximately 1g of calcium chloride was taken in the cell and the polymeric films 
measuring 3.14 cm2 areas were fixed over the brim with the help of an adhesive. The cells 
were weighed accurately and initial weight is recorded, and then kept in a closed desiccator 
containing saturated solution of potassium chloride (approximately 200 ml). The   humidity 
inside the desiccator was measured by a hygrometer, and it was found to be in between 80% 
and 90% RH. The cells were taken out and weighed after 18, 36, 54, and 72 hours.    
 
 From increase in weights, the amount of water vapor and the rate at which water 
vapor transmitted was calculated by using the following formula. 
                                     
                                                WVT rate     =     WL 
                                                                              S                          
                                        Where, W = water vapor transmitted (in g) 
                                                      L = thickness of the film (in cm) 
                                                      S = exposed surface area (in cm2) 
WVT through films determines the permeability characters of the films.                                        
Drug content uniformity64 
 The prepared patch was cut into small pieces and put into 100 ml dissolution or 
diffusion medium used respectively and stirred continuously using a mechanical stirrer and 
sample was with drawn at the end of three hours and the drug content was determined, 
spectrophotometrically at 270 nm. 
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Stability study64, 67 
 Stability of a product may be defined as the capability of particular formulation in a 
specific container to remain with the physical, chemical, microbiological, therapeutic and 
toxicological specifications. The stability studies were conducted according to ICH 
guidelines. The prepared patches were stored for three months at different temperatures 
40°C ± 2° C temperature and at relative humidity of 75% ± 5% RH. The stability study was 
conducted with regard to tensile strength, moisture content and drug content. The patches, 
which retained their physical properties, were further subjected to in-vitro permeation 
studies. 
 
10.7 IN VITRO SKIN PERMEATION STUDIES OF TRANSDERMAL 
PATCH 64, 67, 69, 74 
Preparation of excised Albino Rat skin 
 Albino rats weighing 150-200 g were selected for permeation studies and the 
study was conducted with the approval of institutional ethical committee. The Rat was 
sacrificed using anesthetic ether, hair of test animal was carefully trimmed short (<2 mm) 
with a pair of scissors. Approximately 4.5 to 5.0 Sq cm of full thickness of skin was excised 
from the shaved abdomen site. After removal of the subcutaneous fat; the skin sample was 
washed in distilled water. The separated skin was cut into required size and placed in 
polythene bag and stored under freezing condition into the refrigerator until taken for in 
vitro  permeation studies.  
 
In vitro  skin permeation studies 
 Ethical clearance for the handling of experimental animals was obtained from the 
institutional animal ethical committee (IAEC) formed for this purpose. The protocol of the 
animal study was approved by the Institutional Animal Ethical committee, Protocol 
Number: SVCP/IAEC/M.Pharm/03/2009 dt 07.11.09.  The experiment was conducted 
according to the guidelines of CPCSEA (Committee for the purpose of control and 
supervision of experiment on animals). 
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 These studies were carried out using a mammalian rat skin of required thickness. 
The permeation cell used for this study was a specially fabricated “Modified Franz diffusion 
cell”.  
 
Modified Franz diffusion cell 75,76,77  
 Modified Franz diffusion cell is a skin permeation system developed by Franz and 
commercialized by crown glass has been frequently used for the studying the kinetics of 
Percutaneous absorption. The modified Franz diffusion cell has receptor compartment with 
an effective volume approximately 60 ml and an effective surface area of permeation of 3.14 
sq cms. A rod shaped magnetic stirrer driven by a 3w synchronized motor stirs the solution 
in the receptor compartment. The stirring magnet rotates at constant rpm in a low viscosity 
receptor compartment. 
 
 
 
 
 
 
 
 
 
 
 
 
    Fig 13:  Modified Franz diffusion cell 
Operation of diffusion cell 
 The skin was mounted and clamped between the receptor and donor compartments. 
The surface area exposed to the drug patch was 3.14 sq cm. The cell was maintained at 
37°±0.5°C using thermostatically controlled water bath. Water from the water bath was 
circulated through the cell, which was maintained at constant flow. The diffusion cell of 60 
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ml capacity was filled with phosphate buffer pH 7.4 and fixed to a thermostatically 
controlled magnetic stirrer, which was also maintained at the temperature 37° ±0.5°C. 
At each sampling interval, samples were withdrawn and were replaced by equal 
volumes of fresh receptor fluid on each occasion. Samples withdrawn were analyzed 
spectrophotometrically at 270 nm. 
10.8 KINETIC CHARACTERISTICS OF THE DRUG RELEASE 78, 79  
 To know the mechanism of the drug release from the patches, the results obtained 
from the In-vitro dissolution process were fitted into different kinetic equations as follows: 
1.   Zero - order drug release: Cumulative % drug release Vs Time. 
2. First Order drug release: Log cumulative % drug retained Vs Time. 
3. Higuchi’s classical diffusion equation: Cumulative % drug release Vs Square 
root of time. 
4. Peppa’s Korsemeyer Exponential equation: Cumulative % drug release Vs Log 
time. 
1. Zero order kinetics 
Zero order release would be predicted by the following equation:- 
At = A0 – K0t 
Where, 
 
At  =  Drug release at time‘t’. 
  A0  =  Initial drug concentration. 
   K0  =  Zero - order rate constant (hr-1). 
When the data is plotted as cumulative percent drug release versus time, if the plot is 
linear then the data obeys Zero – order equal to K0. 
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2. First Order Kinetics 
First – order release would be predicted by the following equation:- 
Log C = log C0 – Kt / 2.303 
Where,  
C    =  Amount of drug remained at time‘t’. 
C0  = Initial amount of drug. 
K   =  First – order rate constant (hr-1). 
When the data is plotted as log cumulative percent drug remaining versus time yields 
a straight line, indicating that the release follow first order kinetics. The constant ‘K’ can be 
obtained by multiplying 2.303 with the slope values. 
3. Higuchi’s model 
Drug release from the matrix devices by diffusion has been described by following 
Higuchi’s classical diffusion equation: - 
Q = [Dε / τ (2 A - εCs) Cst] ½ 
Where,    
           Q  =  Amount of drug released at time‘t’. 
D  =  Diffusion coefficient of the drug in the matrix. 
A  =  Total amount of drug in unit volume of matrix. 
Cs  =  the solubility of the drug in the matrix. 
ε  =  Porosity of the matrix. 
τ  =  Tortuosity. 
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t = Time (hrs) at which ‘q’ amount of drug is released. 
Above equation may be simplified if one assumes that ‘D’, ‘Cs’ and ‘A’ are 
constant. Then equation becomes:-           Q = Kt1/2 
When the data is plotted according to equation i.e. cumulative drug release versus 
square root of time yields a straight line, indicating that the drug was released by diffusion 
mechanism. The slope is equal to ‘K’. 
4. Korsemeyer equation / Peppa’s model 
To study the mechanism of drug release from the transdermal patches, the release 
data were also fitted to the well-known exponential equation (Korsemeyer equation/ Peppa’s 
law equation), which is often used to describe the drug release behavior from polymeric 
systems. 
Mt / Mα = Ktn 
Where, 
Mt / Mα =  The fraction of drug released at time‘t’. 
K   =  Constant incorporating the structural and geometrical  
   characteristics of the drug / polymer system. 
n   =  Diffusion exponent related to the mechanism of the release. 
Above equation can be simplified by applying log on both sides, 
Log Mt / Mα = Log K + n Log t 
When the data is plotted as log of drug released versus log time, yields a straight line 
with a slope equal to ‘n’ and the ‘K’ can be obtained from y – intercept. For Fickian release 
‘n’ = 0.5 while for anomalous (non - Fickian) transport ‘n’ ranges between 0.5 and 1.0.  
‘n’ values can be used to characterize diffusion release mechanism as : 
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n < 0.5 Fickian diffusion 
0.5 > n < 1 Non-fickian diffusion 
n > 1 Class – II transport 
 
THE STUDY OF IN VITRO SKIN PERMEATION KINETICS81, 82: 
Permeability coefficient (P): Permeability coefficient is the velocity of drug passage 
through the membrane in mg/cm2/day. It was calculated from the slope of the graph of 
percentage of drug transported versus time as,  
                                                    
                                                P = slope × Vd/S 
                        Where, Vd = volume of donor solution; 
                                       S = surface area of tissue. 
 
Flux (J): Flux is defined as the amount of material flowing through a unit cross-sectional 
barrier in unit time. It is calculated by, 
                                                      J = P × CD 
                       Where, CD = concentration donor solution; P = permeability 
Enhancement ratio (Er): Enhancement ratio was used to evaluate the effect of permeation 
enhancer on diffusion and permeation of selected drug molecules. It is calculated by, 
                 Enhancement ratio =    Permeability coefficient of drug with enhancer 
                                                      Permeability coefficient of drug alone 
. 
10.9 SKIN IRRITATION TEST FOR PATCHES67, 68, 69, 83 
Ethical clearance for the handling of experimental animals was obtained from the 
institutional animal ethical committee (IAEC) formed for this purpose. The protocol of the 
animal study was approved by the Institutional Animal Ethical committee, Protocol 
Number: SVCP/IAEC/M.Pharm/03/2009 dt 07.11.09.  The experiment was conducted 
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according to the guidelines of CPCSEA (Committee for the purpose of control and 
supervision of experiment on animals). 
 
The skin irritation test was done on a healthy rabbit weighing between 2 to 3 kg. The 
rabbits were to be divided into 5 groups with three each. On the previous day of the 
experiment, the hair on the back side of the rabbit is to be removed. Drug   loaded polymeric 
film of 3.14 sq cm was placed on the left dorsal surface of the rabbit. The skin was 
examined for erythema/edema. 
 
Group – I : Served as normal, without any treatment 
Group – II : Control- applied with marketed official adhesive tape in USP 
Group – III : Blank – applied with drugless polymeric patch 
Group – IV :  Test – applied with drug loaded polymeric patch 
Group – V :    Applied with 0.8% v/v aqueous solution of formalin solution as  
                         standard irritant. 
   
 The animals were applied with new patch/formalin solution each day up to 7days and 
finally the application sites were to be graded according to a visual scoring scale. 
The erythema scale is as follows: 
0. none 
1. slight 
2. well defined 
3. moderate 
4. scar formation 
The edema scale is as follows: 
0. none 
1. slight 
2. well defined 
3. moderate 
4. severe 
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Fig 14: Skin irritation test on rabbit 
 
10.10 STATISTICAL ANALYSIS BY ANOVA 
 The in-vitro permeation data were statistically compared and analyzed using Graph 
Pad In stat – 3 software version. The Tukey – Kramer multiple comparisons test was utilized 
to find the ‘q’ and ‘p’ values and the significance of the formulations were studied. 
 If the ‘p’ is <0.05, the formulations are said to be significant 
 
10.11 IN-VIVO ANIMAL STUDIES84 
Six Wister rats of 180-220gm weight are to be utilized for the study. The rats are to 
be allowed to acclimatize for 1 week before the day of administration. The rats are fasted, 
but allowed access to water on the day before the study 
 
Standard concentration solution of lamivudine5 
 A mixture of acetonitrile and water (65:35%V/V) was used as the mobile phase and 
C18 column as the stationary phase. A stock solution of the pure drug was prepared by 
dissolving 50 mg of lamivudine in 50ml of the mobile phase. This stock solution was further 
diluted with the mobile phase to obtain the concentration of 10µg/ml. six samples of this 
concentration are prepared. And observed in HPLC. 
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Fig: 15   Transdermal patch on rat abdomen 
          Six groups of rats are taken for animal studies. Each group containing one rat. Rats are 
to be anesthetized before the experiment. The hair on the abdominal site is clipped before 
the experiment. The skin was gently wiped between warm water and alcohol swab and 
patted dry. 3.14sq.cm size patch with 5mg amount of drug is to be fixed over the skin. Blood 
samples of approximately 0.15 ml were collected in dried heparinzed tubes at 0.5, 2, 4, 8, 16 
and 24hr after transdermal administration from the jugular vein and, as soon as possible, 
they are frozen at -20ºC and store until analysis. 
The HPLC analytical reports of blood samples collected at different hours were compared 
with that of the standard concentration of lamivudine. 
 
10.12 IN-VITRO / IN-VIVO CORRELATION85 
Invitro-invivo correlation is the demonstration of the direct relationship of in vitro  
dissolution rate / diffusion rate of drugs and their in vivo bioavailability. Generally, the in 
vitro  property is the rate or extent of drug dissolution or release while the in vivo response is 
the plasma drug concentration or amount of drug absorbed86. Correlation is used to ensure 
batch-to-batch consistency in the physiologic performance of a drug product by use of such 
in vitro  values and to serve as a tool in the development of a new dosage form with desired 
in vivo performance.  
 There are two basic approaches by which a correlation between dissolution/diffusion 
testing and bioavailability can be developed.  
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1. By establishing a relationship, between the in vitro  dissolution/diffusion and the in 
vivo bioavailability parameters. If this relationship becomes linear with a slope of 1, 
then curves are super imposable, and there is a 1:1 relationship which is defined as 
point-to-point or level A correlation.  
 
2. By using the data from previous bioavailability studies to modify the 
dissolution/diffusion methodology in order to arrive at meaningful in vitro -invivo 
correlation.  
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11.0 RESULTS 
 
Transdermal Matrix patch was prepared with the aim to reduce first pass 
metabolism and there by increasing the bioavailability of the drug. It also reduces the 
frequency of dosing which in turn improve patient compliance and reduce fluctuation in 
plasma drug levels.  
 
The calibration curve was prepared with phosphate buffer pH 7.4. The physical 
mixture of Drug, polymer and the mixture of drug and polymers were subjected to 
compatibility study using FTIR absorption spectra. The fabricated transdermal patches were 
subjected to various evaluation parameters like, Thickness of the patch, Folding endurance, 
Percentage of moisture absorption, Percentage of moisture loss, Water vapor transmission, 
Drug content uniformity, Stability studies, In-vitro skin permeation studies, Skin irritation 
test, Statistical analysis by ANOVA,  In-vivo studies and In-vitro & In-vivo correlation. 
    
Compatibility study 
The drug was identified and confirmed by FTIR spectrum. Fig-16 showed the IR 
spectrum of Lamivudine. Fig-17 shows the IR spectrum of hydroxy propyl methyl cellulose. 
Fig-18 shows the IR spectrum of ethyl cellulose. Fig-19 shows the physical mixture of 
Lamivudine and hydroxy propyl methyl cellulose. Fig-20 shows the physical mixture of 
Lamivudine and ethyl cellulose. 
 
From the Fig-19 and Fig-20, it were concluded that the drug along with the polymers 
showed no change in any characteristic peak of the drug, which confirms that there is no 
interaction between the drug and the polymer used in the fabrication of transdermal patch. 
The presence of peaks at the expected range confirms that the materials taken for the study 
are genuine. 
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Characteristic peaks of drug in FT-IR spectra 
Table-11 
S. No Wave in cm-1 Functional group 
1 3076.75 
C-H Aromatic 
stretching 
2 3213.19 NH2 group 
3 1650.95 Carbonyl group 
4 3326.96 -OH group 
5 1317.29 C-O Bending group 
6 626.82 C-S Bending group 
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Standard curve of Lamivudine 
 Table no.13 and Fig-19 shows the standard curve for Lamivudine in phosphate 
buffer pH 7.4. The method obeyed Beer’s law limit in the concentration range of 10-60 
mcg/ml at 270 nm. 
        Standard Curve 
                                                            Table-12  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Slope         :  0.042261 
                                    Regression:  0.998248 
 
 
  
 
 
 
 
 
Concentration 
(mcg/ml) 
Absorbance at 
270 nm 
0 0 
10 0.103 
20 0.200 
30 0.291 
40 0.380 
50 0.474 
60 0.560 
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Fig: 21 Standard curve of Lamivudine. 
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Physicochemical Evaluation of the prepared Transdermal patches 
 
 Table 13 and 14 shows the physicochemical evaluation like the Thickness, 
Folding endurance, Percentage moisture absorbed, Percentage moisture lost, Drug 
content uniformity. 
Table 13:  Physicochemical Evaluations 
Formulation 
Code 
*Thickness 
(mm) 
*Folding 
endurance 
*% Moisture     
absorbed 
*% 
Moisture 
lost 
*Water 
vapor 
transmission 
rate 
F1 0.250±0.85 140±1.4 2.88±0.80 1.20±0.50 0.112±0.002 
F2 0.282±0.65 124±1.8 2.32±0.70 1.10±0.75 0.125±0.001 
F3 0.323±0.90 98±1.0 1.95±1.10 1.05±0.90 0.134±0.004 
F4 0.345±1.0 160±1.2 2.78±1.50 1.45±1.00 0.153±0.005 
 
*Average of three values  
 ±  Standard deviation 
 
 
Table- 14:  Drug content uniformity 
Formulation 
Code 
Percentage of drug in 3.14 Sq. cms Standard 
Deviations 
1 2 3 4 5 *Mean 
F1 98.2 98.4 98.6 98.4 98.2 98.3 ±0.16 
F2 97.5 98.2 97.2 97.8 98.4 97.8 ±0.49 
F3 95.6 96.2 95.1 95.9 96.6 95.8 ±0.57 
F4 92.7 92.1 94.7 93.9 93.2 93.3 ±1.01 
 
*Average of five values  
 ±  Standard deviations 
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Stability study 
The stability studies conducted reveled that polymeric patches of Lamivudine 
prepared with the polymers, Hydroxy propyl methyl cellulose and Ethyl cellulose in the 
ratios of 1:2.5 and 1:5 with 3% plasticizer, Glycerol were found to be most stable with 
respect to drug content and all the physical parameters evaluated (Table-13 & 14). Hence, 
the patches were suitable for further studies. 
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IN VITRO  SKIN PERMEATION STUDIES OF TRANSDERMAL PATCH 
 
Table- 15 In vitro  Skin Permeation of control formulation-F1W 
(Without permeation enhancer) 
 
 
      
       
       *Average of three values 
       ±  Standard deviations 
Time 
(hrs) 
Cumulative % of 
Drug permeation *Mean 
Standard 
deviations 
(±SD) Trial I Trial II Trial III 
0 0 0 0 0 0 
0.25 0.56872 0.511848 0.654028 0.578199 0.071562 
0.5 1.43128 1.37346 1.518009 1.440916 0.072755 
0.75 2.592417 2.533649 2.680569 2.602212 0.073948 
1 4.341232 3.769668 5.198578 4.436493 0.719202 
2 6.402844 5.821801 7.274408 6.499684 0.731129 
4 8.781991 8.191469 9.667773 8.880411 0.743056 
6 12.19431 11.60379 13.08009 12.29273 0.743056 
8 18.50711 17.89763 19.42133 18.60869 0.766911 
10 23.92417 23.30521 24.85261 24.02733 0.778838 
12 27.72038 27.09194 28.66303 27.82512 0.790765 
14 31.2891 30.65118 32.24597 31.39542 0.802692 
16 36.61611 35.96872 37.5872 36.72401 0.814619 
18 42.30806 41.65118 43.009 42.32275 0.679029 
20 45.52607 44.85972 46.52085 45.63555 0.835963 
22 47.93365 47.25782 48.94265 48.04471 0.84789 
24 51.78199 51.09763 52.80379 51.89447 0.858624 
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Fig 22: In vitro  skin permeation of formulation –F1W 
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Fig 23: Zero order permeation profile of formulation F1 W 
 
                       
                             
                    
 
 
Fig 24: First order permeation profile of formulation F1 W 
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Fig 25: Higuchi permeation profile of formulation F1 
 
                              
                             
                                
 
 
 
Fig 26: Korsemeyer peppa’s permeation profile of formulation F1 W 
 
 
                               
 
 
 
 
 
 90
Table- 16 In vitro Skin Permeation of control formulation- F2 W 
(Without permeation enhancer) 
        
        
         
             *Average of three values 
             ±  Standard deviations 
 
 
 
Time 
(hrs) 
Cumulative % of 
Drug permeation *Mean 
Standard 
deviations 
(±SD) Trial I Trial II Trial III 
0 0 0 0 0 0 
0.25 3.127962 2.559242 3.412322 3.033175 0.434367 
0.5 8.014218 7.436019 8.303318 7.917852 0.441607 
0.75 11.55924 10.97156 11.85308 11.4613 0.448846 
1 14.87678 14.27962 15.17536 14.77725 0.456086 
2 18.81517 18.20853 19.11848 18.71406 0.463325 
4 21.96209 21.34597 22.27014 21.8594 0.470565 
6 25.37441 24.75829 25.68246 25.27172 0.470565 
8 28.69194 28.05687 29.00948 28.5861 0.485044 
10 32.5545 31.90995 32.87678 32.44708 0.492283 
12 37.04265 36.38863 37.36967 36.93365 0.499522 
14 41.59716 40.93365 41.92891 41.48657 0.506762 
16 43.94313 43.27014 44.27962 43.83096 0.514001 
18 48.87678 48.19431 49.21801 48.76303 0.521241 
20 51.32227 50.63033 51.66825 51.20695 0.52848 
22 54.08057 53.37915 54.43128 53.96367 0.53572 
24 56.87204 56.16114 57.22749 56.75355 0.542959 
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         Fig 27: In vitro  skin permeation of formulation – F2 W 
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Fig 28: Zero order permeation profile of formulation F2 W 
        
 
                            
 
 
 
Fig 29: First order permeation profile of formulation F2 W 
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Fig 30: Higuchi permeation profile of formulation  F2 W 
 
 
 
                            
                    
 
 
Fig 31: Korsemeyer peppa’s permeation profile of formulation F2 W 
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Table- 17 In vitro Skin Permeation of control formulation- F3 W 
(Without permeation enhancer) 
        
 
 
         
        *Average of three values 
        ±  Standard deviation 
 
 
 
 
 
 
 
Time 
(hrs) 
Cumulative % of 
Drug permeation *Mean  
Standard 
deviations 
(±SD) Trial I Trial II Trial III 
0 0 0 0 0 0.043437 
0.25 0.56872 0.511848 0.597156 0.559242 0.044161 
0.5 1.43128 1.37346 1.46019 1.421643 0.044885 
0.75 2.592417 2.533649 2.621801 2.582622 0.436539 
1 3.772512 3.200948 4.058294 3.677251 0.443779 
2 5.255924 4.674882 5.546445 5.159084 0.451018 
4 7.616114 7.025592 7.911374 7.517694 0.451018 
6 10.74408 10.15355 11.03934 10.64566 0.465497 
8 16.16114 15.55166 16.46588 16.05956 0.472736 
10 19.54976 18.93081 19.85924 19.4466 0.479976 
12 22.13744 21.509 22.45166 22.0327 0.487215 
14 25.90047 25.26256 26.21943 25.79415 0.494455 
16 28.8673 28.21991 29.191 28.7594 0.501694 
18 31.59242 30.93555 31.92085 31.48294 0.508934 
20 34.63981 33.97346 34.97299 34.52875 0.516173 
22 37.16114 36.48531 37.49905 37.0485 0.523413 
24 39.43128 38.74597 39.77393 39.31706 0.043437 
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Fig 32: In vitro skin permeation of formulation – F3 W 
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Fig 33: Zero order permeation profile of formulation F3 W 
 
                    
                             
                          
 
 
Fig 34: First order permeation profile of formulation F3 W 
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Fig 35: Higuchi permeation profile of formulation F3 W 
 
 
                            
 
 
 
Fig 36: Korsemeyer peppa’s permeation profile of formulation F3 W 
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Table- 18 In vitro  Skin Permeation of control formulation- F4 W 
(Without permeation enhancer) 
 
 
        
                    
        *Average of three values 
        ±  Standard deviation 
 
 
 
 
 
 
Time 
(hrs) 
Cumulative % of 
Drug permeation *Mean  
Standard 
deviations 
(±SD) Trial I Trial II Trial III 
0 0 0 0 0 0 
0.25 1.137441 1.080569 1.165877 1.127962 0.043437 
0.5 2.578199 2.520379 2.607109 2.568562 0.044161 
0.75 3.473934 2.903318 3.759242 3.378831 0.435815 
1 4.952607 4.372512 5.242654 4.855924 0.443055 
2 6.170616 5.581043 6.465403 6.072354 0.450294 
4 8.260664 7.661611 8.56019 8.160821 0.457534 
6 10.53555 9.936493 10.83507 10.4357 0.457534 
8 13.11374 12.49573 13.42275 13.01074 0.472013 
10 17.58768 16.96019 17.90142 17.4831 0.479252 
12 21.27962 20.64265 21.5981 21.17346 0.486491 
14 28.44076 27.79431 28.76398 28.33302 0.493731 
16 31.16588 30.50995 31.49384 31.05656 0.50097 
18 33.92891 33.26351 34.26161 33.81801 0.50821 
20 38.15166 37.47678 38.4891 38.03918 0.515449 
22 41.01422 40.32986 41.3564 40.90016 0.522689 
24 46.47393 45.78009 46.82085 46.35829 0.529928 
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Fig 37: In vitro skin permeation of formulation – F4 W 
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Fig 38: Zero order permeation profile of formulation F4 W 
 
                            
              
                      
                     
Fig 39: First order permeation profile of formulation F4 W 
 
                
                            
 
 
 
 
 
 101
Fig 40: Higuchi permeation profile of formulation F4 W 
 
 
                            
 
 
 
 
Fig 41: Korsemeyer peppa’s permeation profile of formulation F4 W 
           
  
 
                            
 
                      
 
      
 
 102
Table- 19 In-vitro skin permeation of all formulations 
 
(Without permeation enhancer) 
                                  
     
 
 
 
 
Time 
Cumulative % of Drug Permeation 
F1 W F2 W F3 W F4 W 
0 0 0 0 0 
0.25 0.578199 3.033175 0.559242 1.127962 
0.5 1.440916 7.917852 1.421643 2.568562 
0.75 2.602212 11.4613 2.582622 3.378831 
1 4.436493 14.77725 3.677251 4.855924 
2 6.499684 18.71406 5.159084 6.072354 
4 8.880411 21.8594 7.517694 8.160821 
6 12.29273 25.27172 10.64566 10.4357 
8 18.60869 28.5861 16.05956 13.01074 
10 24.02733 32.44708 19.4466 17.4831 
12 27.82512 36.93365 22.0327 21.17346 
14 31.39542 41.48657 25.79415 28.33302 
16 36.72401 43.83096 28.7594 31.05656 
18 42.32275 48.76303 31.48294 33.81801 
20 45.63555 51.20695 34.52875 38.03918 
22 48.04471 53.96367 37.0485 40.90016 
24 51.89447 56.75355 39.31706 46.35829 
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Fig 42: In vitro skin permeation profile of various formulations  
(without permeation enhancer) 
 
 
         
comparitive profile of different formulations
0
10
20
30
40
50
60
0 5 10 15 20 25 30
time (in hrs)
cu
m
u
la
tiv
e 
%
 
dr
u
g 
pe
rm
ea
tio
n
F1W
F2W
F3W
F4W
 
 
 
 
 
 
 
 
 
 104
Table 20: Cumulative Percentage And Kinetic Value Obtained From Different 
Formulations 
ormulation 
Code 
Zero-order First-order Higuchi Korse-  Meyer Peppa's 
Possible  
mechanism  
of drug release 
n R2 n R2 n R2 n R2 
F1W 2.1976 0.9964 0.013 0.993 11.656 0.9603 0.8269 0.9768 
zero-order,  
Non-fickian 
F2W 2.1354 0.9836 0.0138 0.955 11.189 0.985 0.9353 0.9617 
zero-order,  
Non-fickian 
F3W 1.6622 0.9985 0.009 0.9270 8.8468 0.9732 0.7975 0.9844 
zero-order,  
Non-fickian 
F4W 1.8367 0.9921 0.0104 0.9813 9.6014 0.9303 0.7590 0.9437 
zero-order,  
Non-fickian 
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Table 21: In vitro Skin Permeation of formulation-FPE1 
(With permeation enhancer span 3%) 
 
 
 
                  
                 *Average of three values 
                  ±  Standard deviations 
 
 
 
 
 
 
Time 
(hrs) 
Cumulative % of 
Drug permeation *Mean 
Standard 
deviations 
(±SD) Trial I Trial II Trial III 
0 0 0 0 0 0 
0.25 9.383886 8.530806 9.952607 9.2891 0.715624 
0.5 11.24645 10.37915 11.82464 11.15008 0.727551 
0.75 15.98104 15.09953 16.56872 15.8831 0.739478 
1 18.80095 17.90521 19.3981 18.70142 0.751405 
2 25.64455 24.7346 26.25118 25.54344 0.763332 
4 34.87204 33.94787 35.48815 34.76935 0.775259 
6 38.85308 37.92891 39.46919 38.75039 0.775259 
8 43.16588 42.21327 43.80095 43.06003 0.799114 
10 46.11848 45.43602 46.76303 46.10585 0.663597 
12 54.79621 53.81991 55.45024 54.68878 0.820457 
14 57.91943 56.92891 58.58294 57.81043 0.832385 
16 63.92417 62.91943 64.59716 63.81359 0.844312 
18 68.0237 67.00474 68.70616 67.91153 0.856239 
20 74.16588 73.1327 74.85782 74.05213 0.868166 
22 76.69668 75.64929 77.3981 76.58136 0.880093 
24 80.95735 79.89573 81.66825 80.84044 0.89202 
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                            Fig 43: In vitro skin permeation of formulation – FPE1 
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Fig 44: Zero order permeation profile of formulation FPE1 
 
 
                            
 
Fig 45: First order permeation profile of formulation FPE1 
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Fig 46: Higuchi permeation profile of formulation FPE1 
 
 
 
                            
 
 
 
Fig 47: Korsemeyer peppa’s permeation profile of formulation FPE1 
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                   Table 22: In vitro Skin Permeation of formulation- FPE2 
                                         (With permeation enhancer span 3%) 
 
 
 
        *Average of three values 
         ±  Standard deviations 
 
 
 
 
 
 
 
Time 
(hrs) 
Cumulative % of 
Drug permeation *Mean  
Standard 
deviations 
(±SD) Trial I Trial II Trial III 
0 0 0 0 0 0 
0.25 11.09005 10.23697 11.65877 10.99526 0.715624 
0.5 12.98104 12.11374 13.55924 12.88468 0.727551 
0.75 17.74408 16.86256 18.33175 17.64613 0.739478 
1 20.59242 19.69668 21.18957 20.49289 0.751405 
2 27.46445 26.5545 28.07109 27.36335 0.763332 
4 36.72038 35.79621 37.33649 36.61769 0.775259 
6 40.70142 39.77725 41.31754 40.59874 0.775259 
8 45.07109 44.11848 45.70616 44.96524 0.799114 
10 48.05213 47.08531 48.69668 47.94471 0.811041 
12 56.75829 55.77725 57.41232 56.64929 0.822968 
14 59.90995 58.91469 60.57346 59.79937 0.834895 
16 65.94313 64.93365 66.61611 65.83096 0.846822 
18 70.07109 69.04739 70.75355 69.95735 0.858749 
20 76.24171 75.20379 76.93365 76.12638 0.870676 
22 81.64455 80.59242 82.34597 81.52765 0.882603 
24 88.82464 87.75829 89.53555 88.70616 0.89453 
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Fig 48: In vitro skin permeation of formulation – FPE2 
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Fig 49: Zero order permeation profile of formulation FPE2 
 
 
 
                            
 
 
                        
 
Fig 50: First order permeation profile of formulation FPE2 
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Fig 51: Higuchi permeation profile of formulation FPE2 
 
 
                             
 
                        
 
Fig 52: Korsemeyer peppa’s permeation profile of formulation FPE2 
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Table 23: In vitro Skin Permeation of formulation- FPE3 
(With permeation enhancer span 3%) 
 
 
 
                *Average of three values 
               ±  Standard deviations 
 
 
 
 
 
 
Time 
(hrs) 
Cumulative % of 
Drug permeation *Mean 
Standard 
deviations 
(±SD) Trial I Trial II Trial III 
0 0 0 0 0 0 
0.25 2.843602 1.990521 3.412322 2.748815 0.715624 
0.5 5.450237 4.582938 6.028436 5.35387 0.727551 
0.75 7.530806 6.649289 8.118483 7.432859 0.739478 
1 11.35071 10.45498 11.94787 11.25118 0.751405 
2 14.09479 13.18483 14.70142 13.99368 0.763332 
4 17.7346 16.81043 18.35071 17.63191 0.775259 
6 20.86256 19.93839 21.47867 20.75987 0.775259 
8 26.31754 25.36493 26.95261 26.21169 0.799114 
10 31.56872 30.6019 32.21327 31.4613 0.811041 
12 33.77251 32.79147 34.42654 33.66351 0.822968 
14 38.56398 37.56872 39.22749 38.4534 0.834895 
16 41.15166 40.14218 41.82464 41.03949 0.846822 
18 45.19431 44.17062 45.87678 45.08057 0.858749 
20 50.71564 49.67773 51.40758 50.60032 0.870676 
22 52.33649 51.28436 53.03791 52.21959 0.882603 
24 57.38389 56.31754 58.09479 57.2654 0.89453 
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Fig 53: In vitro skin permeation of formulation – FPE3     
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Fig 54: Zero order permeation profile of formulation FPE3     
 
                            
 
 
 
Fig 55: First order permeation profile of formulation FPE3 
 
                            
 
  
                      
 
 116
 
Fig 56: Higuchi permeation profile of formulation FPE3 
 
 
 
                            
 
 
 
 
Fig 57: Korsemeyer peppa’s permeation profile of formulation FPE3 
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Table 24: In vitro Skin Permeation of formulation- FPE4 
 
(With permeation enhancer span 3%) 
 
 
 
       
        *Average of three values 
        ±  Standard deviations 
 
 
 
 
Time 
(hrs) 
Cumulative % of 
Drug permeation *Mean  
Standard 
deviations 
(±SD) Trial I Trial II Trial III 
0 0 0 0 0 0 
0.25 3.981043 3.127962 4.549763 3.886256 0.715624 
0.5 6.322275 5.454976 6.900474 6.225908 0.727551 
0.75 8.985782 8.104265 9.57346 8.887836 0.739478 
1 12.54502 11.64929 13.14218 12.4455 0.751405 
2 14.73934 13.82938 15.34597 14.63823 0.763332 
4 18.95735 18.03318 19.57346 18.85466 0.775259 
6 21.51659 20.59242 22.1327 21.4139 0.775259 
8 27.28436 26.33175 27.91943 27.17852 0.799114 
10 32.83412 31.8673 33.47867 32.7267 0.811041 
12 35.05687 34.07583 35.7109 34.94787 0.822968 
14 39.8673 38.87204 40.53081 39.75671 0.834895 
16 42.47393 41.46445 43.14692 42.36177 0.846822 
18 51.08531 50.06161 51.76777 50.97156 0.858749 
20 56.98578 55.94787 57.67773 56.87046 0.870676 
22 62.40284 61.35071 63.10427 62.28594 0.882603 
24 65.90521 64.83886 66.61611 65.78673 0.89453 
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Fig 58: In vitro skin permeation of formulation – FPE4     
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Fig 59: Zero order permeation profile of formulation FPE4 
 
 
 
                             
   
Fig 60: First order permeation profile of formulation FPE4 
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Fig 61: Higuchi permeation profile of formulation FPE4 
 
 
                            
 
 
 
 
Fig 62: Korsemeyer peppa’s permeation profile of formulation FPE4 
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Table- 25 In-vitro skin permeation of all formulations  
 
(With permeation enhancer) 
 
 
 
 
 
 
  
                          
 
Time 
Cumulative % of Drug Permeation 
FPE1 FPE2 FPE3 FPE4 
0 0 0 0 0 
0.25 9.2891 10.99526 2.748815 3.886256 
0.5 11.15008 12.88468 5.35387 6.225908 
0.75 15.8831 17.64613 7.432859 8.887836 
1 18.70142 20.49289 11.25118 12.4455 
2 25.54344 27.36335 13.99368 14.63823 
4 34.76935 36.61769 17.63191 18.85466 
6 38.75039 40.59874 20.75987 21.4139 
8 43.06003 44.96524 26.21169 27.17852 
10 46.10585 47.94471 31.4613 32.7267 
12 54.68878 56.64929 33.66351 34.94787 
14 57.81043 59.79937 38.4534 39.75671 
16 63.81359 65.83096 41.03949 42.36177 
18 67.91153 69.95735 45.08057 50.97156 
20 74.05213 76.12638 50.60032 56.87046 
22 76.58136 81.52765 52.21959 62.28594 
24 80.84044 88.70616 57.2654 65.78673 
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Fig 63: In vitro skin permeation profile of various formulations  
(with permeation enhancer) 
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Table 26: Cumulative Percentage And Kinetic Value Obtained From Different 
Formulations 
 
Formulation 
Code 
Zero-order First-order Higuchi Korse-  Meyer Peppa's Possible 
mechanism  
of drug release 
n R2 n R2 n R2 n R2 
FPE1 3.0056 0.9857 0.0264 0.9534 15.732 0.9923 0.8534 0.9866 
zero-order,  
Non-fickian 
FPE2 3.1432 0.9910 0.0310 0.950 16.231 0.9857 0.9429 0.9786 
zero-order,  
Non-fickian 
FPE3 2.1968 0.991 0.0139 0.979 11.57 0.9827 0.5304 0.968 
zero-order,  
Non-fickian 
FPE4 2.4947 0.9852 0.0172 0.9718 12.982 0.956 0.546 0.9426 
zero-order,  
Non-fickian 
 
 
. 
 
.     
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The in vitro skin permeation kinetics: 
Table-27: The in vitro skin permeation kinetic data for transdermal patches 
(Without permeation enhancer) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The in vitro skin permeation kinetics: 
Table-28: The in vitro skin permeation kinetic data for transdermal patches 
(With permeation enhancer) 
 
 
 
 
 
 
 
S. No Formulation Code 
Slope of 
zero order 
plot 
Permeation 
coefficient  
(P) 
Flux 
(J) 
1 F1  W 2.1354 3.40 17 
2 F2  W 2.1976 3.49 17.45 
3 F3  W 1.6622 2.64 13.2 
4 F4  W 1.8362 2.92 14.6 
S. No Formulation Code 
Slope of 
zero order 
plot 
Permeation 
coefficient  
(P) 
Flux 
(J) 
Enhancement 
ratio (Er) 
1 FPE1 3.005 4.78 23.9 1.405 
2 FPE2 3.143 5.00 25 1.432 
3 FPE3 2.196 3.49 17.45 1.321 
4 FPE4 2.494 3.97 19.85 1.359 
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Skin irritation test 
 The visual score was 0 (none) on both the erythema scale and the edema scale. 
This indicates there was no sign of skin reaction. Hence, the fabricated transdermal patch 
was suitable for further studies.     
 
 
Statistical analysis by ANOVA 
The statistical analysis of the cumulative percentage of drug permeation data 
showed that the formulations are having ‘p’ value < 0.0001. This result suggests that the 
prepared Transdermal patches are extremely significant for the approach 
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IN-VIVO STUDIES FOR THE BEST FORMULATION (FPE2) 
 
HPLC analytical data for the plasma and control samples. 
 
Table- 29 
 
 
 
S. 
No Sample  
                                                Area under curve (AUC) 
Trial 1 Trial 2 Trial 3 Trial 4 Trial 5 Trial 6 
1 Control 1729250.73 1729330.15 1729300.93 1729200.69 1729190.39 1729230.58 
S.
No 
Sample 
Time 
(in hrs) 
Rat 1 Rat 2 Rat 3 Rat 4 Rat 5 Rat 6 
2 0.5 1429283.25 1429363.54 1429333.19 1429233.70 1429223.92 1429263.66 
3 2 2914583.07 2914563.11 2914523.29 2914533.57 2914633.72 2914663.85 
4 4 3787204.87 3787154.19 3787284.74 3787144.57 3787254.48 3787184.30 
5 8 5039821.69 5039761.07 5039871.39 5039841.55 5039901.17 5039771.91 
6 16 5785842.70 5785922.03 5785792.22 5785822.64 5785892.91 5785782.44 
7 24 6874342.48 6874392.12 6874322.60 6874422.55 6874282.28 6874292.88 
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In-vivo drug absorption kinetics  
Table- 30   
 
 
S. No Time(in hrs) 
Mean Area 
under curve 
(AUC) 
Concentration 
(µg/ml) 
% drug 
absorption 
(%) 
1 control 1729250.73 10  
-- 
2 0.5 1429283.25 8.265 16.54 
3 2 2914583.07 16.85 33.71 
4 4 3787204.87 21.90 43.80 
5 8 5039821.69 29.14 58.28 
6 16 5785842.70 33.45 66.90 
7 24 6874342.48 39.75 79.50 
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In-vivo absorption studies 
 
 
 
 
In-vivo absorption profile
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Fig: 64 In-vivo absorption curve 
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 Fig: 65 HPLC analysis of standard solution of Lamivudine 
 
 
 
 
 
 
 
 
 130
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig: 66 HPLC analysis of rat plasma after 0.5hrs 
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 Fig: 67 HPLC analysis of rat plasma after 2 hrs 
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Fig: 68 HPLC analysis of rat plasma after 4 hrs 
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Fig: 69 HPLC analysis of rat plasma after 8hrs 
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Fig: 70 HPLC analysis of rat plasma after 16 hrs 
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Fig: 71 HPLC analysis of rat plasma after 24 hrs 
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INVITRO/INVIVO CORRELATION: 
 
Table- 31  
 
 
 
 
By establishing a relationship, between the in vitro permeation and the in vivo absorption 
parameters. 
 
 
 
Fig: 72 Comparitive curve for Invitro & Invivo studies. 
 
 
 
S.No Time 
(in hrs) 
In-vitro skin permeation 
(%) 
In-vivo absorption (%) 
1. 0.5 12.88 16.54 
2. 2 27.36 33.71 
3. 4 36.61 43.80 
4. 8 44.96 58.28 
5. 16 65.83 66.90 
6. 24 88.70 79.50 
comparitive in-vitro & in-vivo drug release
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Table- 32 Comparison of Invitro and Invivo studies 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Slope- 0.814983 
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Fig: 73 Linear curve for In vitro/In vivo correlation. 
By establishing a relationship, between the in vitro permeation and the in vivo absorption 
parameters. The slope for these parameters is 0.814983. so, they are said to be near  
correlated, and the curves are not super imposable. 
 
 
In-vitro skin permeation 
(%) 
In-vivo absorption (%) 
12.88 16.54 
27.36 33.71 
36.61 43.80 
44.96 58.28 
65.83 66.90 
88.70 79.50 
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12. DISCUSSION 
                The topical and transdermal drug delivery system has gained wide range of 
applications in the field of drug delivery systems. The most common barrier for this type 
of system is to deliver the drug through skin via dermal and transdermal route. 
                 The transdermal drug delivery system has gained popularity over the past few 
decades. Transdermal therapeutic system has generated an interest as this system 
provides the considerable advantage of a non-invasive parenteral route for drug therapy, 
avoidance of first-pass, gut and hepatic metabolisms, decreased side effects and relative 
ease of drug input termination in problematic cases. The major penetration pathway of 
drug molecules through the stratum corneum of intact human skin is by diffusing through 
the lipid envelopes of the skin cells. 
                The Nucleoside analog reverse transcriptase inhibitors have become the first-
line therapy in treating HIV patients. Lamivudine has been used for treatment of chronic 
hepatitis B at a lower dose than for treatment of HIV. It improves the seroconversion of 
e-antigen positive hepatitis B and also improves histology staging of the liver. Long term 
use of lamivudine unfortunately leads to emergence of a resistant hepatitis B virus 
(YMDD) mutant. Despite this, lamivudine is still used widely as it is well tolerated.. 
Most of the Nucleoside analog reverse transcriptase inhibitors inhibitors are bi-peptides 
that are too hydrophilic to dissolve and penetrate through the lipid layers. Lamivudine 
was selected among the Nucleoside analog reverse transcriptase inhibitors due to the 
molecular size, therapeutic dose, half-life and to have a chronic treatment for the disease. 
 Lamivudine is an analogue of cytidine. It can inhibit both types (1 and 2) of 
HIV reverse transcriptase and also the reverse transcriptase of hepatitis B. It has been 
widely used for the treatment of HIV and Hepatitis B. The drug is considered a drug of 
choice in anti-retroviral therapy due to its effectiveness and low toxicity. Lamivudine 
shows 80% bio-availability, but presence of food reduces the Cmax and tmax, there is no 
change in its bioavailability. The sustained release of drug cannot be obtained with the 
oral administration and a chronic treatment is necessary for the HIV disease. Therefore, 
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the use of transdermal drug delivery system can reduce the side effects associated with 
conventional dosage forms and the frequent of dose administration can be reduced. 
           The preliminary study conducted on compatibility between Lamivudine, HPMC 
and EC revealed that there is no interaction between the drug and polymer.  
Dose designing 
 Drug input rate across the skin was calculated to be 0.2067 mg/hr (Table-9). 
Therefore, the total drug required for 24 hr drug delivery is 5.0 mg. 
 
THE TRANSDERMAL PATCHES 
           The polymers are the backbone for transdermal delivery. Some of the widely used 
polymers for the fabrication of transdermal patches are Cross-linked poly ethylene glycol 
(PEG) networks, Acrylic-acid matrices, Ethyl cellulose (EC), polyvinylpyrrolidone 
(PVP), Hydroxy propyl methyl cellulose (HPMC), Organogels, Ethyl vinyl acetate 
(EVA) co-polymers, and Chitosan etc. Among these polymers, HPMC and EC was 
selected for preparation of patches. Since, HPMC and EC are used as rate controlling 
polymers for sustained release and also they acts as stabilizing agent and having the 
property to inhibit oxidation. Hence, they are commonly employed in formulation of 
patches. 
 
           The Physico-chemical characteristics such as thickness of the patch, folding 
endurance, percentage of moisture absorbed, percentage of moisture lost, and water vapor 
transmission rate were found to be within the acceptable limits. The Patches were found 
to stable to withstand the stress.  
 
 Stability studies: All the patches were found to be most stable as per ICH 
guidelines. 
 
In vitro skin permeation studies of Transdermal Patches: 
The results of the in vitro skin permeation profile demonstrated that duration of 
sustained release of the patches appears to depend on characteristics and concentration of 
HPMC and EC. As the concentration of HPMC and EC increased, the cumulative 
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percentage sustained releases were FPE1 (80.840±0.894), FPE2 (88.706±0.894), FPE3 
(57.265±0.894), FPE4 (65.786±0.892) for 24hrs respectively with permeation enhancer 
patches (Fig. 63), the cumulative % sustained releases were F1W (51.894±0.858), F2W 
(56.753±0.542), F3W (39.317±0.043), F4 W (46.358±0.529) for 24hrs respectively without 
permeation enhancer patches (Fig. 42). An ideal transdermal delivery system should 
show sustained release characteristics. Taken this into account, the formulation F2 met the 
above objective and hence, it was selected for in- vivo studies.  
 
The results indicated that span 80 greatly influenced the permeation of the drug 
through the skin. Thus, suggesting the use of permeation enhancer in transdermal drug 
delivery system. The permeation profiles of the patches (Table-26) showed the regression 
value greater for zero order release than the first order release and the diffusion release 
constant (n) value in korsmeyer peppa’s plot was found to be in the range of  0.5 < n < 
1.0 ,thus concludes the mechanism of drug release as zero order and non-Fickian release 
(Anomalous). 
 
The in vitro skin permeation data analysis 
 The permeability parameters like steady-state flux (J), permeability coefficient 
(P), and enhancement ratio (Er) were significantly increased in formulations containing 
permeation enhancers. The permeability parameters of different formulations are given in 
tables 27 & 28 
 
Skin irritation test 
Any topical application should not produce skin irritation. This study was carried 
out on rabbit skin; it is observed that the transdermal patches are free from skin irritation.   
 
Statistical analysis by ANOVA 
 The statistical analysis of the cumulative percentage of drug permeation data 
showed that the formulations are having ‘p’ value < 0.0001. This result suggests that the 
prepared Transdermal patches are extremely significant for the approach. 
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The in - vivo drug absorption data analysis 
        The in-vivo studies are performed for the best formulation selected from the in-vitro 
skin permeation studies.i.e, (FPE2) formulation was selected. The HPLC 
spectrophotometer is used for analysing the plasma samples. The in-vivo drug absorption 
studies (Fig. 64) reveals that there is a sustained release of drug into the rats systemic 
circulation of 79.5% of drug absorption was found after 24hrs.   
 
 In-vitro/In-vivo correlation 
By establishing a relationship, between the in vitro skin permeation studies and 
the in vivo absorption studies (Fig. 73). If this relationship becomes linear with a slope of 
1, then curves are super imposable, and there is a 1:1 relationship which is defined as 
point-to-point or level - A correlation.  
In the present study the slope between the in vitro skin permeation studies and the 
in vivo absorption studies was 0.814983. So, they are said to be near correlated, and the 
curves are not super imposable and are not linear. 
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13. CONCLUSION 
  
The prepared Transdermal patch showed good sustained release properties. The 
results of the present study demonstrated that Lamivudine and HPMC in the ratio 1:5 
(FPE2) showed a good sustained release characteristic with the 3% Span 80 as a 
permeation enhancer, thus providing a better way of preventing first pass metabolism, 
frequent administration of drug and obtaining a sustained release effect for chronic 
treatment of HIV disease. The in-vitro skin permeation studies (FPE2) showed a best 
sustained release effect over other formulations. The comparative statistical analysis done 
by ANOVA method proved that all the formulations are extremely significant for the 
Transdermal route. The in-vivo studies (FPE2) also showed a sustained release effect of 
the drug into the systemic circulation. The in vitro /in vivo correlations are found to be 
not super imposable and said to be near correlated. Further in-vivo studies in detail and 
extrapolation of the data will help in development of a transdermal patch for clinical use. 
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